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Liver diseases are associated with hepatocytes damage. Currently, liver transplant is the only 
treatment for liver failure. A shortage of donors has forced extensive research for alternative 
treatments. The most promising hepatocyte source could be obtained from the differentiation 
of induced pluripotent stem cells (iPSCs). This technology can give us great amounts of 
pluripotent cells without any ethical restrictions which could be available in variety of 
haplotypes to minimize the possibility of rejection. From those stem cells, it is possible to 
obtain hepatic-like cells (HLCs). However, they show fetal liver identity. Varieties of hepatic 
differentiation protocols were described, although the process of hepatic differentiation still 
needs to be improved. Along with genes, microRNA (miRNA) is the well-known controller of 
cell fate. In contrast to genes, many miRNAs can affect up to thousands of genes 
simultaneously. Another group of non-coding RNA (ncRNA) that is a subject to potential 
differences are small nucleolar RNA (snoRNA). SnoRNA are involved in RNA chemical 
modifications by acting as a guide, mostly for ribosomal RNA (rRNA).  
In this study, a new iPSCs line was generated from skin fibroblasts and characterized. Next, 
HLCs were derived from those iPSCs using a four-stage hepatic differentiation protocol, and 
ncRNA sequencing was performed to compare the expression profiles of HLCs at two stages 
of differentiation (day 20 and 24) with mature hepatocytes. The involvement of miRNAs and 
snoRNAs in the dynamics of hepatic differentiation was explored in order to shed light on the 
molecular and regulatory mechanisms that underlie this complex process. Obtained HLCs 
maintain an epithelial characteristic and express miRNA, which can block maturation by 
inhibiting Epithelial-Mesenchymal Transition (EMT). In addition, differentially expressed 






A1AT – Human Serpin peptidase inhibitor 
AFP – α-fetoprotein 
ALB – Albumin 
BMP4 – bone morphogenetic protein 4 
DAPI – 4',6-Diamidino-2-Phenylindole, Dilactate  
E-cadherin – epithelial cadherin 
ECM – extracellular matrix 
EMT – Epithelial to mesenchymal transition  
ESCs – embryonic stem cells 
FDA – The Food and Drug Administration  
FDR – False Discovery Rate (adjusted p-value) 
GFP – Green fluorescent protein 
HLCs – Hepatocyte like cells  
HNF4a – Hepatic nuclear factor 4 α 
ICG – Indocyanine green 
iPSCs – Induced pluripotent stem cells 
KEGG - Kyoto Encyclopedia of Genes and Genomes 
Klf4 – Kruppel-like factor 4 
linkRNA – long intergenic noncoding RNA 
MET – mesenchymal to epithelial transition  
miRNA – Micro RNA, plural miRNAs 
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miscRNA – miscellaneous RNA 
mRNA – Messenger RNA 
MRR2 – multidrug resistance protein 2 
MSCs – mesenchymal stem cells 
N-cadherin – neural cadherin 
ncRNA – non-coding RNA 
Oct4 – Octamer-binding transcription factor 4 (POU5F1) 
PAS – Periodic acid shift  
PP1 – Protein phosphatase 1  
PSCs – pluripotent stem cells 
q-PCR – quantitative PCR 
Snail – Zinc finger protein SNAI1 
snoRNA – Small nucleolar RNA, plural snoRNAs 
snRNA – small nuclear RNA 
Sox2 – SRY (sex determining region Y)-box 2 
WGA – Wheat Germ Agglutinin 
ZEB1 – Zinc finger E-box-binding homeobox 1 
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1. Introduction  




The pluripotency of the cells is defined as a capability to self-renewal and differentiation into 
all body cells. Two types of the pluripotent stem cells (PSCs) can be distinguished: naturally 
occurring embryonic stem cells (ESCs) and generated in vitro induced pluripotent stem cells 
(iPSCs) (Laustriat, Gide, & Peschanski, 2010). The ESCs can be derived from the inner cell 
mass of a blastocyst. The first mouse ESCs were isolated independently by Ewans and 
Kauffman and as well by Martin in 1981 (Evans & Kaufman, 1981; Martin, 1981). This 
discovery sparked hopes that those cells may be useful to treat many degenerative diseases as 
a source of cells for transplantation or tissue engineering. However, human cells originating 
from an early-stage preimplantation embryo create many controversies. Despite this, in 1998 
human ESCs were isolated from in vitro fertilized embryos donated for scientific purposes 
(Thomson et al., 1998). One of the obstacles to use those ESCs in clinics was an 
incompatibility with a broad number of patients. There were many attempts to obtain 
embryonic cells which genetically match the patient. The first successful somatic cell nuclear 
transfer (SCNT) was performed on the sheep embryo and later another mammal and human 
embryos were used (Campbell, McWhir, Ritchie, & Wilmut, 1996; Polejaeva et al., 2000; 
Tachibana et al., 2013). The essence of this process is to transfer a differentiated cell nucleus 
into the oocyte from which the nucleus has been previously removed. This process is very 
inefficient and requires usage of hundreds of oocytes to obtain one of the modified embryo. 
Nevertheless, this experiment demonstrated that some unknown factors present in the 
cytoplasm of the egg cells cause changes in the nuclei of somatic cells and revert them to the 
embryo. Pluripotent cells can be obtained also by fusion of the undifferentiated cells with 
mature ones (Miller & Ruddle, 1976). This was achieved already in 1976 when Miller and 
Ruddle showed that thymocytes fuse with cancer embryonic stem cells. Similar results have 
been obtained by electrofusion of mature cells with embryonic stem cells of mice and humans 
(Flasza et al., 2003). However, chimeric cells are not suitable for the medical purpose. Based 
on the hypothesis that the ESCs contain factors that keeps them pluripotent Takahashi and 
Yamanaka have selected 24 proteins which were tested for the ability to restore pluripotent 
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phenotype in somatic cells. In 2006, they discovered that overexpression of four transcription 
factors: Oct4, Sox2, Klf4, and c-Myc induces pluripotency in mature cells (Takahashi et al., 
2007; Takahashi & Yamanaka, 2006). This led to emergence of new kind of stem cells called 




Figure 1 Origin and biological properties of PSCs.  
Source: (Laustriat et al., 2010). 
 
Morphologically, pluripotent stem cells can be described as small, round cells with a large 
nucleus. PSCs grow in colonies with the support of feeder layer or extracellular matrix. 
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During standard culture, a small fraction of the cells undergoes spontaneous differentiation. 
Determination of the phenotype of cells is extremely important for the usage of those cells in 
the clinic (Adewumi et al., 2007). The pluripotent cells when deprived of factors maintaining 
their undifferentiated phenotype, form embryoid bodies, which is an intermediate step in the 
differentiation into all types of cells. Among the pluripotency gene expression analysis, 
scientist developed methods of testing functionally newly derived iPSCs. One of those tests is 
teratoma formation assay. It is performed by injection of iPSCs into nude mice strain which 
exhibits impaired immune response. Teratomas composed of cells derived from all three germ 
layers proves the differentiation potential of the injected cells. Two more methods confirming 
differentiation in vivo are not performed on human cells for ethical reasons. The injection of 
iPSCs into developing blastocyst and observation of their integration during embryonic 
development is called a blastocyst complementation assay. It is convenient to observe 
incorporation of the cells expressing reporter gene for example GFP. Developed chimera 
should show the presence of the reporter gene in the tissues from different germ layers (Tam 
& Rossant, 2003). The second method called tetraploid blastocyst complementation assay 
uses a tetraploid embryo, usually tetraploid morula, formed by electrofusion of two 
blastomeres. The created tetraploid cells are mixed with diploid iPSCs, and then the newly 
created embryo is implanted into the uterus of the animal. Tetraploid cells can produce only 
extraembryonic tissue, and if the diploid cells are pluripotent, the whole organism will 
develop normally (Kang, Wang, Zhang, Kou, & Gao, 2009). The latest method is based on 
microarray analysis of iPSCs and comparison to the created database as an alternative to high 




The first reprogramming of somatic cells was preceded by selecting factors that may restore 
the pluripotent nature of somatic cells. For this purpose, Takahashi and Yamanaka created 
mouse line "Fbx βgeo/βgeo" by homologous recombination of the Fbx15 gene substituting 
gene β-geo which codes among others, neomycin resistance gene (G418). The Fbx15 gene 
encodes a protein that is expressed only in embryonic stem cells, however, lack of its 
expression does not interfere with the embryonic development of mice. 24 transcription 
factors were chosen for testing and introduced by retroviral vectors to embryonic fibroblasts 
isolated from mouse Fbx βgeo/βgeo. The cells with gene overexpression were then checked 
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for resistance to G418. Individually none of the factors caused such resistance appearing 
together enable the induce antibiotic resistant colonies. During further analysis, 4 transcription 
factors were selected: Oct4, Sox2, Klf4, and c-Myc which induce pluripotency effectively. 
The reprogrammed cells express pluripotent markers and genes. They could also create 
teratomas consisting of tissues derived from the three germ layers and form in vitro embryoid 
bodies. Injected into the mouse blastocyst, could create the chimeric organism proving 
definitively the pluripotent character (Takahashi & Yamanaka, 2006).   
 
1.1.3. Reprogramming methods 
 
Starting from reprogramming breakthrough, many scientists sought to improve the process to 
make it safer and more efficient. A year after the first pluripotency induction in mouse 
fibroblasts, reprogramming of human somatic cells was achieved. Skin fibroblasts from the 
36-year-old woman were transduced with retroviral vectors containing “four Yamanaka’s 
factors”. The process of reprogramming human cells was twice as long because of the slower 
proliferation of human cells. It has been shown that obtained iPSCs resemble human ESCs 
(Takahashi et al., 2007). Two reprogramming factors: c-Myc and Klf4 are well-known 
oncogenes which overexpression can lead to the formation of cancer. A group of American 
scientists proved the possibility of using some other factors in the reprogramming process 
identified by comparing gene expression of ESCs and bone marrow-derived stem cell line. 
Using a set of four genes: Oct4, Sox2, NANOG and LIN28 they demonstrated that human 
foreskin fibroblasts can be successfully reprogrammed into iPSCs (Yu et al., 2007). The next 
step in the process of improving the technique of cell reprogramming was to use a single 
polycistronic vector including four factors in one expression cassette. This approach reduced 
the amount of integration of exogenous genes into the cellular genome which may cause 
mutations (Sommer et al., 2009). Lentiviral vectors find to be more effective tools than 
retroviral vectors, but the efficiency of reprogramming with them was still low (0.1%) 
(Stadtfeld, Maherali, Breault, & Hochedlinger, 2008). Adding small molecule compounds, 
which activate reprogramming, was one of the attempts to increase the efficiency of the 
process. One of such compounds is valproic acid which allowed reprogramming of human 
cells with only two genes: Oct4 and Sox2 (Huangfu et al., 2008). Nevertheless, integration of 
the introduced genes into the genome of the transduced cells involves a high risk of mutations 
and reduces the possibility of using such modified cells in regenerative medicine. Therefore, 
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alternative methods for cell reprogramming were investigated. Okita et al. showed that 
plasmid vectors in combination with electroporation are sufficient, while the team of Konrad 
Hochedlinger managed to obtain iPSCs using adenoviral vectors (Okita, Hong, Takahashi, & 
Yamanaka, 2010; Stadtfeld, Nagaya, Utikal, Weir, & Hochedlinger, 2008). In both cases, the 
introduced exogenes did not integrate into the cellular genome, but these methods have low 
efficiency (Oh et al., 2012). Higher efficiency can be obtained by using transposons, but this 
method requires an additional step of selecting cells which significantly complicates and 
prolongs the reprogramming process (Yusa, Rad, Takeda, & Bradley, 2009). The transfection 
of somatic cells with synthetic mRNA molecules was one of the latest developed approaches 
which eliminate the risk of integration of the inserted sequences (Warren et al., 2010; 
Yakubov, Rechavi, Rozenblatt, & Givol, 2010). The very high efficiency of reprogramming 
human cells isolated from different tissues was an additional advantage of this approach. 
Zhou et al. went even further and showed that it is possible to obtain iPSCs using 
transcription factors in the form of recombinant proteins (Zhou et al., 2009). Such modified 
proteins had linked polyarginine anchor to the C-end and could migrate to the cell nuclei 
where they remain for 48 hours. The resulting iPSCs exhibit markers and morphology of 
human embryonic stem cells. The possibility of obtaining iPSCs by transduction with a 
lentiviral vector containing a single cluster microRNA demonstrated by Anokye-Danso et al. 
was another breakthrough in the development of new methods for reprogramming (Anokye-
Danso et al., 2011). Overexpression of Mir-302/367 cluster induced pluripotency in mouse 
and human fibroblasts. Moreover, this process was two times more efficient than a standard 
method of gene transduction, but valproic acid was required. Valproic acid inhibits histone 
deacetylase 2 (HDAC2) activity which is responsible for chromatin condensation. Cells 
quickly respond to the miRNAs because one miRNA can act on multiple target mRNA and its 
action does not involve the production of proteins. Miyoshi et al. connected the two latest 
methods of obtaining iPSCs by the transfection of cells with mature, synthetic miRNAs. 
Multiple transfections with three produced miRNAs (mir-200c, mir-302, and mir-369) 
effectively reprogrammed mouse and human fibroblasts (Miyoshi et al., 2011). For more than 
10 years, the process of cell reprogramming has been carefully investigated. Many other 
genes were discovered to influence the process. For example, inhibition of the Mbd3, a core 
member of the Mbd3/NuRD (nucleosome remodelling and deacetylation) repressor complex, 
together with Yamanaka’s factors (OSKM) transduction give almost 100% of reprogramming 
efficiency in mouse and human cells (Rais et al., 2013). Within the next few years, 
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reprogramming for clinical approach will likely become a fully standardized method without 
genome modification. 
 
Figure 2 Gene delivery systems for cell reprogramming.  
Source: (Oh et al., 2012). 
 
1.1.4. IPSCs as an alternative cell source for disease modelling and regenerative 
medicine 
 
The PSCs can be an unlimited source of cells for medical purpose as a consequence of their 
self-renewal and differentiation potential. The biggest concern is to prove that transplanted 
cells integrate and do not create teratomas. A clinical approval of the PSCs derivatives 
requires a full multi-phase drug pipeline process, which is long and expensive, but already in 
progress. The ESCs are now in clinical trials for eye diseases, spinal cord injury, myocardial 
infarct, Parkinson disease and diabetes (Chapman & Scala, 2012; Fields, Cai, Gong, & Del 
Priore, 2016; Menasché et al., 2015; Schulz, 2015; Schwartz et al., 2015). Many other 
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potential applications are registered and waiting for approval to start the trials. Those 
experimental procedures are in the first phase of the clinical trials which were designed to 
prove their safety. So far, there have been no reports of adverse effects (Trounson & DeWitt, 
2016). The iPSCs derivatives have been used once on an individual to treat age-related 
macular degeneration in Japanese clinical trial (Fields et al., 2016). Improvements in vision 
were observed and more patients were included in the trial, however, one of the autologous 
iPSCs lines developed mutation during in vitro culture. The clinical trial was stopped. In the 
near future, it is planned for patients to obtain allogenic iPSCs with proven genetic stability.  
A cell transplantation is an essential objective in the iPSCs research, however, those cells also 
revolutionised the field of diseases modelling and toxicology. The possibility to culture 
patient-derived iPSCs is beneficial for studying disease aetiologies and to develop new 
treatments (Burkhardt et al., 2013; Ren et al., 2015). It is possible to recapitulate 
differentiation process and obtain large amounts of cells for drugs testing (Young et al., 
2015). As an outcome, personalized medicine can arise with the aim of identifying the most 
potent therapy for patients with diverse genetic backgrounds (Avior, Sagi, & Benvenisty, 
2016). To improve safety and standardisation of iPSCs production stem cell banks were 
initiated. In those facilities, iPSCs are generated under good manufacturing practice (GMP) 
conditions and stored. Cells will be there carefully monitored and characterised for medical 
purpose. As an alternative to autologous iPSCs, human leukocyte antigen (HLA) homozygous 
cells will be reprogrammed to reduce the possibility of cells rejection for many patients 
worldwide (Taylor, Peacock, Chaudhry, Bradley, & Bolton, 2012; Zimmermann, Preynat-
Seauve, Tiercy, Krause, & Villard, 2012) This step will be necessary for future safe use of 
those cells. Now, commercially available GMP-qualified iPSCs produced by Lonza could be 
an alternative for clinicians (Baghbaderani et al., 2015). Although iPSCs clinical potential is 








1.2. Liver  
 
1.2.1. Liver anatomy and function 
 
A human liver is located in the upper right quadrant of the abdomen and can be divided into a 
right and a left lobe. Histologically, a liver structure is complex and highly organized. The 
liver functional unit called lobule consist of plates of hepatocytes radiating from a central vein 
and portal triads located on the periphery (Fig. 3) (Saxena, Theise, & Crawford, 1999). The 
portal triad is composed of the portal vein, bile duct, and hepatic artery in the sinuous. The 
liver tissue is built in 80% by hepatocytes and consists also other cell types (Kmiec, 2001). 
Bile ducts are made up from cholangiocytes which can resorb water from bile salts. The 
endothelial cells, stellate cells, and Kupffer cells are nonparenchymal liver cells which 
supports liver functions but are of mesodermal origin. The stellate cells also known as Ito 
cells, lipocytes, perisinusoidal cells, or vitamin A-rich cells is the major cell type involved in 
liver fibrosis (Hautekeete & Geerts, 1997), whereas Kupffer cells are resident macrophage 
population in the liver (Dixon, Barnes, Tang, Pritchard, & Nagy, 2013). The liver receives 
venous blood directly from the intestine, spleen, and pancreas by hepatic portal vein which 
covers approximately 75% of the livers blood supply. The remaining one quarter is delivered 
by hepatic arteries. Receiving nutrients, hormones and toxins as the first organ, uncover 
complex functions which liver performs. The liver filters certain substances from the blood 
and metabolises them. Components of the body like hormones, such as estrogen, aldosterone 
and anti-diuretic hormone are metabolised as well as potential exotoxins: alcohol and other 
drugs. The liver stores vitamins (A, D, E, K, B12), copper and iron. Bilirubin released after 
red blood cells break down is metabolised into ferritin. The hepatocytes are also involved in 
protein degradation which produces urea and regulation of carbohydrates metabolism by 
storing glycogen. The liver produces components of the blood: albumin, prothrombin, 
fibrinogen and some globulin. Additionally, the liver is an accessory digestive gland and 
produces bile salts which help to digest lipids by emulsification (Laker, 1990; Malarkey, 





Figure 3 Liver structure and cell types. (A) Organisation of hepatic lobule, hepatocyte 
cords radiate from the central vein (CV). (B) Cell types in the liver.  
Source: (Gordillo, Evans, & Gouon-Evans, 2015). 
 
In the liver hepatocytes form a cell layer that separates blood from the canalicular bile. Unlike 
the other epithelial cells which are polarized in the plane of the tissue, hepatocytes contribute 
to creating capillary-like structures, the bile canaliculus. Apical and basolateral plasma 
membrane differ in cell adhesion molecules, cell junctions, membrane transporters and 
extracellular matrix (Gissen & Arias, 2015). On the apical side, membrane creates microvilli. 
These structures increase the surface area of the canalicular membrane and facilitate secretion 
of bile. In culture, primary hepatocytes and cell lines have significant limitations to create bile 
canaliculi and only collagen sandwich cultures allow recreating cell polarity so far (Knop, 
Bader, Böker, Pichlmayr, & Sewing, 1995; Müsch, 2014). Another type of polarisation occurs 
in hepatic lobule. This phenomenon is called metabolic zonation (Gebhardt, 1992; 
Jungermann & Kietzmann, 2000). A heterogeneous population of hepatocytes can be 
distinguished in the axis between hepatic vein and veins leaving the liver. Close to the portal 
vein, which is in contact with hepatic artery and the bile ducts, there are situated periportal 
hepatocytes. These cells receive blood rich in oxygen and nutrients, but also are exposed to 
contact with toxins. On the opposite side, around a hepatic centrilobular vein, there are 
located perivenous hepatocytes. Those cells are major protein producers in the liver. 
Hepatocytes form different compartments, vary in expression of enzymes and membrane 
transporters. 
The liver has great regeneration potential, however, under pathological conditions it can 
suffer many diseases (Taub, 2004). Hepatitis is a liver inflammation, mostly caused by virus 
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infection or heavy alcohol abuse. Chronic hepatitis can be a cause of liver failure or cancer. 
Excessive alcohol consumption can be a starting point for other liver diseases: fatty liver 
disease and cirrhosis. Large vacuoles filled with triglycerides appear in hepatocytes during 
fatty liver disease (Cohen, Horton, & Hobbs, 2011). A nonalcoholic fatty liver disease is 
linked to obesity and insulin resistance. Fatty liver is sometimes accompanied by 
inflammation which can progress to more severe forms of the disease. Hepatocyte damage 
and activation of stellate cells lead to fibrosis and consequently to cirrhosis when liver tissue 
is replaced by scar tissue. Typically, this condition develops slowly over the years and is not 
reversible (Schuppan & Afdhal, 2008). Liver injury can also be caused by drugs and toxins. 
Several inherited liver diseases can be distinguished: Wilson's disease, hemochromatosis, 
alpha 1-antitrypsin deficiency. Those diseases affect also other organs and often are 
recognized in adult patients (Kumar & Riely, 1995; Morrison & Kowdley, 2000). 
 
1.2.2. Liver embryonal development 
 
The liver embryonic development is a strictly regulated process. Over the last two decades, 
significant progress has been made in the understanding of the molecular mechanisms 
underlying this process. By studying a mice tissue explant cultures, and by using molecular 
biology techniques, it was possible to identify key factors orchestrating hepatogenesis. 
Despite this interest, no one has studied liver development in humans thoroughly before 
iPSCs techniques allowed researchers to recapitulate hepatogenesis in vitro.  
The liver development starts when outgrowing bud forms on the foregut endoderm. Then the 
basal membrane of the bud delaminates, and cells migrate into surrounding mesenchymal 
septum transversum. During and after migration, the primitive sinusoidal endothelial cells 
form capillary-like structures between hepatic cords. At this stage, hepatoblast which can give 
rise to hepatocytes and cholangiocytes can be distinguished. The hepatic maturation is a 
gradual process which takes place even after birth (Zaret, 2002; Duncan, 2003; Zhao & 
Duncan, 2005; Gordillo et al., 2015). A fetal liver participates in hematopoiesis during 
embryonic development. Determination of the hepatic lineage is therefore strongly influenced 
by mesodermal cells. First, by close contact of the ventral endoderm with the precardiac 
splanchnic mesoderm and second, by the septum transversum mesenchyme. These two events 
are necessary for a complete differentiation of liver. It was shown that without FGF-2 secreted 
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by cardiac mesoderm, the liver formation is repressed, and pancreas develops instead 
(Deutsch, Jung, Zheng, Lóra, & Zaret, 2001). Secretion of bone morphogenetic proteins by 
the septum transversum mesenchyme is critical for hepatoblasts expansion (Rossi, Dunn, 
Hogan, & Zaret, 2001). Additionally, septum transversum is a producer of extracellular 
matrix (ECM). Integrins are receptors to ECM components, built of different combinations of 
α and β subunits. Interestingly, β1 integrin knockout mice die early. Experiments on chimeras 
showed that β1 integrin-deficient cells failed to colonize liver and spleen (Fässler & Meyer, 
1995). It is also believed that endothelial cells support liver development. Inhibition of 
vascular growth during hepatoblast expansion can reverse liver formation (Matsumoto, 
Yoshitomi, Rossant, & Zaret, 2001). Specification of hepatocytes is driven later by the hepatic 
nuclear factor (HGF) and Oncostatin M (Schmidt, Bladt, Goedecke, & Brinkmann, 1995; 
Kamiya et al., 1999).  
During the liver development, several transcriptional factors are sequentially involved in the 
hepatic differentiation as shown in the figure (Kinoshita & Miyajima, 2002). It is worth 
mentioning that Hnf3 and Gata4 were shown to have the ability to open chromatin which 
makes them master transcription regulators of early hepatic lineage commitment (Cirillo et 
al., 2002). Additionally, this transcription factor can directly enhance albumin expression. 
Studies on knockout mice generated for all of the genes expressed during differentiation 
reveals that factors Hex and Hnf4α are crucial for developing a liver. Embryos lacking those 
factors die early due to impaired hepatogenesis (Costa, Kalinichenko, Holterman, & Wang, 





Figure 4 Extra- and intracellular molecules involved in development of liver in different 
stages.  
Underlined molecules were identified from studies of knockout mice.  Source: (Kinoshita 
& Miyajima, 2002). 
 
1.3. Hepatic differentiation of iPSCs in vitro 
 
1.3.1. HLCs  
 
According to the European Liver Transplant Registry, the number of liver transplants is 
plateauing due to a lack of organs (Adam et al., 2003). This leads to the deaths of many 
patients with end-stage liver diseases. Transplantations of human hepatocytes could give hope 
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to people waiting for an organ transplant. Unfortunately, isolated human hepatocytes are 
restricted in number. During the in vitro culture of isolated hepatocytes, cells gradually lose 
their functions. To overcome those limitations, alternative sources of hepatocytes are 
proposed. Porcine hepatocytes were clinically tested for their function as a component of 
extracorporeal hybrid liver support. Despite promising results, this device failed to be 
available for patients after FDA restrictions that prohibit xenogenous cell usage in medicine 
(Im Sauer et al., 2003). Immortalized hepatocyte cell lines, as well as cancer-derived cell 
lines, exhibit some hepatic functions, but due to dedifferentiation and the accumulation of 
mutations in culture, they are not considered as a source of cells for medical purposes 
(Dhawan, Puppi, Hughes, & Mitry, 2010). The isolation of human ESC allows in vitro hepatic 
differentiation to be studied. Despite the challenges and ethical issues, the first hepatic 
differentiation protocols were proposed. Later, after Yamanaka’s discovery of iPSCs, the 
possibility to obtain autologous cell lines gave rise to personalised medicine and pushed 
studies in this field forward. Significant progress has been made in the derivation of HLCs, 
however, recapitulating hepatic functions in vitro is still arduous (Schwartz, Fleming, 
Khetani, & Bhatia, 2014). Obtained HLCs resemble a fetal hepatic characteristic (Baxter et 
al., 2015). Many researchers tried to obtain more mature HLCs using different methods. 
Unfortunately, the comparison of protocols can be difficult due to a lack of standardised 
characterisation methods. Detailed tests should be performed in order to characterise an 
obtained cell identity. Confirming a hepatic lineage commitment can be based on genes and 
proteins expression. HLCs should be of a polygonal or cuboidal shape with large nucleoli. In 
electron microscopy studies, the presence of abundant mitochondria, peroxisomes, and lipid 
bodies should be tested, as well as the presence of microvilli and the bile canalicular network. 
Cell polarisation is a feature of mature hepatocytes. It can be detected by the presence of 
several basal or apical proteins (e.g. MRP-2, CD26). Finally, HLCs should exhibit typical 
hepatic functions. The most popular among characterisation tests are glycogen production, 
albumin production, urea production, and the activity of detoxification enzymes. To test the 
liver replacement of hepatocytes and functional engraftment, several mice models were used; 
nevertheless, they showed a low level of engraftment capacity (Schwartz et al., 2014).  
Infection by the hepatitis C virus is also considered as a proof for hepatic identity (Si-Tayeb, 
Duclos-Vallée, & Petit, 2012; Schwartz et al., 2012). The necessity to perform such an 
enormous work to characterise HLCs makes those cells exceptional. Many laboratories 
collaborate in order to fully characterise and compare obtained cells with isolated hepatocytes 
(Godoy et al., 2015). Recently, commercial HLCs called iCell Hepatocytes form Cellular 
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Dynamics became available for hepatotoxicity test and drug discovery. By using this 
technology, the first attempts to screen new drugs for the treatment of heritable metabolic 
liver diseases, like familial hypercholesterolemia, became possible (Cayo et al., 2017). 
 
1.3.2. Differentiation protocols into hepatocytes 
 
As mentioned before, first attempts to obtain hepatocytes from pluripotent stem cells begin 
after ESC isolation. It was shown that by cell aggregation and the generation of embryoid 
bodies (EB), it was possible to obtain cells from three germ layers, including hepatic 
progenitors (Hamazaki et al., 2001). Later, the mouse ESCs were directly differentiated into 
HLCs (Jones, Tosh, Wilson, Lindsay, & Forrester, 2002). Using a similar approach, human 
HLCs were derived (Rambhatla, Chiu, Kundu, Peng, & Carpenter, 2003). By mimicking 
signals observed during embryonic liver development, protocols from spontaneous 
differentiation events were changed into direct hepatic differentiation with specific cytokine 
cocktails and defined extracellular matrix. In the case of iPSCs, to prove their differentiation 
potential, Yamanaka showed endoderm linage commitment right after their discovery 
(Takahashi et al., 2007). Later, a group from China applied a modified differentiation protocol 
and successfully obtained HLCs from iPSCs (Song et al., 2009). All existing direct 
differentiation protocols can be divided into four parts. First, endoderm induction is an 
essential step for efficient HLCs formation. It can be done by using Activin A 
supplementation combined with the activation of Wnt3a signalling or FGF addition (Hay et 
al., 2008). Many groups, in order to improve efficiency, sorted the cells according to their 
extracellular markers. Recently, the GSK-3 inhibitor - CHIR99021 has been used as an 
alternative in defined differentiation conditions (Mathapati et al., 2016). It was also shown 
that a 24-hour cell exposition to CHIR99021 produces a more homogenous definitive 
endoderm. A hepatic specification with the addition of BMP4 and FGF2 occurs in the second 
phase. Then, there is a hepatoblast expansion phase with HGF supplementation, and finally a 
hepatic maturation with Oncostatin M (Han et al., 2012; Schwartz et al., 2014). Some 
protocols contain DMSO to improve hepatic differentiation (Czysz, Minger, & Thomas, 
2015). However, the usage of DMSO is controversial and some reports show an inhibition of 
differentiation (Pal, Mamidi, Das, & Bhonde, 2012). An extracellular matrix used for 
supporting the cells also can influence hepatic differentiation. Commonly used Matrigel and 
25 
 
their derivatives are not suitable for defined culture conditions. Recently shown 
differentiation of iPSCs on recombinant laminins can be a step forward for the medical usage 
of those cells (Cameron et al., 2015). Attempts to generate HLCs in defined conditions gave 
rise to the protocol using only small molecules (Siller, Greenhough, Naumovska, & Sullivan, 
2015). Another direction is to use 3D culture and bioreactors to improve differentiation 
efficiency (Sivertsson, Synnergren, Jensen, Björquist, & Ingelman-Sundberg, 2012; 
Takayama et al., 2013). Perfused systems allow for the constant control of culture conditions, 
and when compared to standard 2D culture, they produce more mature HLCs (Freyer et al., 
2016). Innovative organs on the chip which are miniature complex bioreactors designed to 
mimic a liver microenvironment in vitro. The hepatic differentiation of iPSCs in those devices 
confirmed that functionality of the HLCs can be elaborated (Caralt, Velasco, Lanas, & 
Baptista, 2014a). To imitate whole hepatocyte niche, a decellularized liver scaffold can be 
used (Caralt, Velasco, Lanas, & Baptista, 2014b). By using this technique, bioengineered 
tissue mimics a natural liver structure. However, there is a necessity for the implementation of 
endothelial progenitors to fill the vascular network (Baptista et al., 2011). Co-culture methods 
demonstrated great potential for liver tissue engineering. A combination of hepatic, 
endothelial, and mesenchymal progenitors spontaneously produces 3D organoids (Shinozawa, 
Yoshikawa, & Takebe, 2016). The self-organizing approach coupled with iPSCs technology 
is the most advanced and complex organoid model (Takebe, Zhang et al., 2014). 
Nevertheless, the acquisition of hepatic functions occurs after transplantation and 
vascularisation of the liver bud (Takebe, Koike et al., 2014). Recently, a similar effort has 
been made to obtain cholangiocyte-like cells from iPSCs (Dianat et al., 2014). Generated 
organ models are useful for studying the molecular mechanism underlying liver development 
and pathogenicity. In the future, these examples will hopefully be the base for developing 




In contrast to genes coding messenger RNA (mRNA), ncRNAs participate mostly in 
regulating gene expression and gene translation. There are many types of ncRNAs that differ 
in structure and function. The ribosomal RNAs (rRNAs), and transfer RNA (tRNAs) are 
involved in mRNA translation. The micro RNA (miRNAs) function as gene silencers. The 
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small nucleolar RNAs (snoRNAs) are involved mostly in the modification of other rRNAs. 
The Small Cajal body RNA (scaRNAs) and related small nuclear RNAs (snRNAs) are 
snoRNAs which are taking part in splicing (Abbas, Raza, Biyabani, & Jaffar, 2016; Isakov et 
al., 2012). The liver miRNAs and snoRNAs will be described here in detail since they are the 
main objectives of this study. 
 
1.4.1. MiRNA  
 
MiRNAs are post-transcriptional gene expression regulators. These 21-22 nucleotide long 
molecules can affect the expression of multiple genes simultaneously by binding to the 
complementary regions of a messenger RNA (mRNA). A large number of miRNA are highly 
conserved in sequences among different organisms (Cai, Yu, Hu, & Yu, 2009; Chen & 
Verfaillie, 2014). MiRNA serve as potential diagnostic and therapeutic targets. The human 
miRNAs are initially transcribed by RNA polymerase II as several hundred-nucleotide long 
miRNA precursors, termed a primary miRNA (pri-miRNA), which contain RNA stem-loop. 
In canonical processing, pri-miRNA is cleaved by Drosha. A shorter hairpin termed a pre-
miRNA that contains a 2 nt 3′ overhang, is the resultant of the cleavage. Then, the pre-
miRNA is exported to the cytoplasm by nuclear Exportin 5 for another cleavage. Enzyme 
Dicer cuts the loop of pre-miRNA leaving 22 base pairs RNA duplexes bearing 2 nt 3′ 
overhangs. One strand of the duplex stays associated with Dicer and is then incorporated into 
the RNA induced silencing complex (RISC). This complex includes protein Argonaute which 
leads the interaction with target mRNA and has nuclease activity. There are also other 
pathways of RISC preventing translation (Cullen, 2004; Winter, Jung, Keller, Gregory, & 
Diederichs, 2009; Inui, Martello, & Piccolo, 2010). Deletion of Dicer is lethal in a mouse. 
Further, it was shown that hepatocytes of recombinant Dicer negative mouse liver (AlbCre; 
Dicer flox/flox), undergo activation of proliferation and apoptosis. Recombinant mouse had 
lack of liver zonation and developed lethal hepatocarcinomas (Sekine, Ogawa, Mcmanus, 
Kanai, & Hebrok, 2009).  
In the liver, the most abundant miR-122 is involved in the metabolism of lipids, glucose, and 
iron as well as in hepatocyte differentiation (Lewis & Jopling, 2010; Hu et al., 2012; Wen & 
Friedman, 2012). It was shown that overexpression of miR-122 enhances expression of 
HNF6, FOXA1, and HNF4a which are the master transcription factors during liver 
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development (Laudadio et al., 2012; Deng et al., 2014). Overexpression of miR-122 can 
enhance hepatic maturation of fetal liver progenitors (Doddapaneni et al., 2013). The miR-122 
can suppress cell proliferation and tumor metastasis by down-regulating the protein levels of 
Wnt1 (Wnt signaling is an inducer of EMT) (Girard, Jacquemin, Munnich, Lyonnet, & 
Henrion-Caude, 2008; Coulouarn, Factor, Andersen, Durkin, & Thorgeirsson, 2009; Xu et al., 
2012). Additionally, its expression enhances replication of the Hepatitis C virus (HCV) 
(Lanford et al., 2010). Another miRNA which is highly expressed in the liver is miR-148. It 
promotes hepatic maturation by targeting DNA methyltransferase 1 (DNMT, dominant de-
novo DNA cytosine methyltransferase in human, responsible for epigenetic silencing) and is a 
tumor suppressor (Gailhouste et al., 2013). Studies on mouse hepatic stem cell line HBC-3 
demonstrated the importance of the miR-23b cluster, which contains miR-23b, miR-27b, 
miR-24-1, miR-10a, miR-26a, and miR-30a in regulating hepatic specification (Rogler et al., 
2009). The miR-23b cluster members repress bile duct gene expression in fetal hepatocytes by 
down-regulating Smads 3, 4, and 5 and as a result of TGFβ signalling. The miR-194 is 
responsible for the preservation of hepatocyte epithelial phenotype by inhibition of N-
cadherin expression and other known prometastatic genes (HBEGF, RAC1, PTPN12, ITGA9, 
SOCS2) (Meng et al., 2010). Moreover, expression of the miR-194 together with miR-192 
and miR-215 is regulated by HNF1a and it was shown that they can inhibit EMT (Krützfeldt 
et al., 2012; Khella et al., 2013).  
In comparison to mature liver, several miRNAs have been found to be highly expressed in 
fetal liver (Fu et al., 2005; Liu et al., 2010; Tang, Liu, Zhang, Ingvarsson, & Chen, 2011). 
Studies on mice have discovered functions of some of those miRNAs. The miR-92b is 
important for hepatic progenitors to proliferate and by targeting CCAAT/enhancer binding 
protein beta (C/EBPß) gene, it can block maturation (Qian et al., 2013). The miR-483, another 
upregulated gene during liver development promotes proliferation in a prooncogenic manner, 
but can inhibit fibrosis by targeting platelet-derived growth factor-β (PDGF-β) and tissue 
inhibitor of metalloproteinase 2 (TIMP2) (Li et al., 2014; Ma et al., 2012). It is important to 
mention that it was possible to initiate hepatic differentiation by overexpression of the seven 
miRNAs (miR-1246, miR-1290, miR-148a, miR-30a, miR-424, miR-542-5p, and miR-122) 
in differentiating human umbilical cord lining-derived mesenchymal stem cells (Cui et al., 
2013). Additionally, when expression of any of these miRNAs was inhibited, the hepatic 






SnoRNAs act as guides for chemical modifications of other RNAs, mainly rRNAs. In the 
humans, snoRNAs are encoded in introns of the host genes. Based on different sequence 
motifs and secondary structures, snoRNAs are divided into two types: box C/D snoRNAs, 
that guide ribose methylation and box H/ACA snoRNAs which guide pseudouridylation 
(Dupuis‐Sandoval, Poirier, & Scott, 2015; Kiss, 2002). Typical box C/D snoRNAs have 
conserved boxes C (consensus sequence RUGAUGA) near their 5′ and D (consensus 
sequence CUGA) at 3′ termini. Usually, they are between 60 and 90 nucleotides long. The 
box C base pairs with D and creates a k-turn which is a binding site for a set of core proteins 
forming a box C/D snoRNP. In the loop region there are additional motifs, boxes C′ and D′. 
Their sequences have the same consensus as the boxes C and D, respectively, but are typically 
less conserved. The target RNA is complementary to the regions upstream of the boxes D′ 
and/or D. The modified nucleotide in the target RNA is the fifth residue upstream of the box. 
Whereas box H/ACA snoRNAs secondary structure consists of two hairpins. They are also 
longer, up to 140 nucleotides. In between the hairpin structures, there is an unpaired region 
that contains conserved motive H box (ANANNA where N can be any nucleotide) called 
hinge. After the second hairpin, upstream of the 3’ end of the molecule in the tail, another 
conserved box called ACA is located. The name reflects the consensus sequence. Targets bind 
complementarily into the pseudouridylation pockets forming small duplexes with the target 
RNA, allowing only few mismatches in the middle of hairpins. The modified uridine is 
typically located 14–16 nucleotides upstream from the conserved boxes where bulges are 
created (Reichow, Hamma, Ferré-D'Amaré, & Varani, 2007). To form functional complexes, 
snoRNAs associate with specific protein components such as GAR-1 (Box H/ACA) or 





Figure 5 Structure of Box C/D and Box H/ACA snoRNAs.  
m3Gppp – trimethylguanosine cap structure on 5’end.  In green highlighted substrate RNAs 
and in red – snoRNAs core motifs. Pseudouridylation (Ψ) and 2′-O-methylation (circled m) of 
the nucleotides are marked. Source: (Kiss, 2002). 
 
ScaRNAs unlike typical snoRNAs, are accumulated and possess additional localization 
motifs. ScaRNAs can have typical box C/D or H/ACA structure, single or tandem or can be a 
hybrid of box C/D and box H/ACA snoRNAs. They target snRNAs (U1, U2, U4, U5, U11, 
U12, U6) (Hebert, 2013). Apart from the canonical function in guiding nucleotide 
modifications, further snoRNA functions have been discovered. SNORD3, SNORD14, 
SNORD22, SNORA63, SNORA73, and SNORD118 are involved in the cleavage of the 
rRNA operon. Several box H/ACA snoRNAs are found to be enriched in chromatin-
associated RNA (caRNA) which are responsible for chromatin decondensation. SCARNA19 
is a telomerase RNA component (TERC) (Dupuis‐Sandoval et al., 2015). Bioinformatic 
methods allow to predict targets for some of snoRNAs guided modifications. SnoRNAs 
without predicted targets are called ‘orphan snoRNA’ and some of them play a role in the 
regulation of alternative splicing (Bazeley et al., 2008). Some specific snoRNAs are known to 
act in a miRNA-like fashion and there are examples of their association with the Argonaute 
protein (Ender et al., 2008; Brameier, Herwig, Reinhardt, Walter, & Gruber, 2011; Burroughs 
et al., 2011). The region SNURF-SNRPN is one of two imprinted regions coding snoRNA. It 
contains five box C/D snoRNA: SNORD64, SNORD107, SNORD108, SNORD109 (two 
copies) and the tandem repeats of SNORD116 and SNORD115 (Runte et al., 2001). An 
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inheritance of deletion in this locus of paternal chromosome causes Prader-Willi syndrome 
(Bieth et al., 2015). Numbers of snoRNAs were recently proposed to be massively processed 
into shorter RNA species, called processed snoRNA (psnoRNA) or sno-derived RNA 
(sdRNA) (Falaleeva & Stamm, 2013a). It was shown that SNORD115-derived short RNA 
regulates alternative splicing of serotonin 2C receptor mRNA (Kishore et al., 2010). In the 
human tissues snoRNAs have been observed to be differentially expressed and have recently 





















Induced pluripotent stem cells revolutionised developmental biology. Now, by using those 
cells, it is possible to follow their natural embryonal development to generate tissues in vitro. 
There are many problems to overcome before the use of iPSCs in medicine can be possible. 
The biggest challenge is to obtain genetically stable pluripotent cell lines with high efficiency. 
Transfection with episomal vectors is currently the most popular method of generating iPSCs. 
However, this method is limited by transfection efficiency. The present thesis aims to 
generate stable iPSCs by overcoming those limitations in order to enable the wide use of 
cellular reprogramming.  
The first aims of the current thesis are: 
- Generation of stable iPSCs through episomal vector transfection, 
- Pluripotency characterization of the generated iPSCs. 
Liver failure is an untreatable disease which causes millions of deaths every year. Liver tissue 
is also very important for the toxicological testing of new drugs. IPSCs which have unlimited 
differentiation potential, can be applied in order to overcome current limitations with 
accessing hepatocytes. Although many hepatic differentiation protocols exist, there is still a 
room for improvement. Obtained hepatic-like cells resemble a fetal liver and thus, their 
functions are impaired. The current thesis will compare HLCs and hepatocytes, with focus on 
the ncRNA, to study the potential inhibitors of hepatic maturation.  
The second aims of the current thesis are: 
- Hepatic differentiation of obtained iPSCs, 
- Characterisation of HLCs 
- Non-coding RNA analysis. 
In summary, the aims of the current study are first, the generation of stable, footprint-free 
iPSCs which can be used for hepatic differentiation, and second, an analysis of the obtained 








• Milli-Q (Millipore) 
• Microscope Olympus IX 51 
• Microscope Nikon eclipse TE2000-S 
• Fluorescence microscope (Zeiss and CTR600 Leica) 
• ND1000 Spectrophotometer (NanoDrop Technologies) 
• Thermocycler Primus 96 plus (MWG AG Biotech) 
• Biosafety cabinet (Heraeus) 
• Applied Biosystems 7500 Real-Time PCR System (Thermo Fisher Scientific) 
• Confocal microscope (Leica Microsystems)  
• Labofuge 400R (Heraeus) 
• Minishaker MS 2 (IKA) 
• Incubator Cytoperm 2(Heraeus) 
• -86°C ULT Freezer (Thermo Forma) 




• MS-Office 2007 SP2 (Microsoft) 
• Leica Software v. 1.4.0 (Leica) 
• Cell^A (Olymus) 
• AxioVision (Zeiss) 
• ImageJ (image analysis) 
• FastQC (sequencing quality) 
• Segemehl (mapping to the genome, Bioinformatics Leipzig) 
• R (The R Foundation) 
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• R Studio (FOAS) 
• Bioconductor package  
• EdgeR package  
• Rnacounter (counting the reads) 
• Bedtools (analysis of the reads) 
• DIANA mirPath V. 3.0 
 
3.3. Enzymes, Kits and Transfection Reagents 
 
• Lipofectamine 3000 transfection reagent (Life Technologies) 
• Trypsin/EDTA (Life Technologies) 
• RNeasy Mini Kit (Qiagen) 
• miRNeasy Micro Kit (Qiagen) 
• Periodic Acid-Schift (PAS) staining system (Sigma-Aldrich) 
• Superscript III Reverse Transcriptase (Thermo Fisher Scientific) 
• CYBR Green PCR master mix (Thermo Fisher Scientific) 
 
3.4. Solutions and reagents 
 
• PBS (Life Technologies) 
• 4% paraformaldehyde Roti-Histofix (Carl Roth GmbH) 
• Versene (LifeTechnologies) 
• 4,6-diamidino-2-phenylindole dilactate (DAPI) (Sigma) 
• BSA powder (PPA) 
• Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich) 
• Dimethyl Sulfoxide (DMSO) Cell culture grade (AppliChem) 
• Opti-MEM® I Reduced Serum Medium (Life Technologies) 
• Penicillin/streptomycin (Life Technologies) 
• Cardiogreen (Sigma-Aldrich) 
• Saponin powder (Sigma-Aldrich) 
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• Nuclease-Free Water (Qiagen) 
• Geltrex ESC qualified (Thermo Fisher Scientific) 
• Wheat Germ Agglutinin, Alexa Fluor® 488 Conjugate (Thermo Fisher Scientific) 
• DAPI (Sigma) 
• Chloroform (Roth) 
• Ethanol (Roth, Sigma) 
• TE Buffer (AppliChem) 
 
3.5. Cell lines 
 
• Gibco Episomal hiPSC line (A18945, Life Technologies) 
• HepG2 cell line (ATCC) 
• Primary cells: isolated human foreskin fibroblasts (HIV, HBV, HCV negative cells 
obtained from 6 years old, healthy boy) 
• Generated cells: iPS cell line (ULEIi001-A) 
• Frozen hepatocytes pooled 10 donors (HMCS10, GIBCO) 
 
3.6. Cell culture media and cytokines  
 
• DMEM low glucose (Thermo Fisher Scientific) 
• Essential 8 (Thermo Fisher Scientific) 
• ESC qualified FBS  
• RPMI1640 medium (Thermo Fisher Scientific) 
• B27 Supplement Minus Insulin (ThermoFisher Scientific) 
• B27 Supplement (ThermoFisher Scientific) 
• Activin A (R&D Systems) 
• Fibroblast growth factor 2 (FGF2, R&D Systems) 
• Bone morphogenetic protein 4 (BMP4, Peprotech) 
• Hepatocyte growth factor (HGF, Peprotech) 
• HCM™ hepatocyte culture medium (Lonza) 
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• Oncostatin M (R&D Systems) 
 
3.7. Plasmids  
 
Table 1 Description of the plasmids used.  
Plasmid Expressed genes Supplier  Cells transfected  
TrueClone Human cDNA 
clone (SC123863) 
Human Hepatocyte Nuclear 
Factor 4  




with GFP reporter gene 
(SC900A) 
Oct4, Sox2, L-Myc, Klf4, 








3.8. PCR reagents and primers 
 
3.8.1. PCR reagents 
 
• Deoxynucleotide triphosphates (dNTPs) (Thermo Fisher Scientific) 
• Oligo(dT)18-Primer (Thermo Fisher Scientific) 
• RNase-Free DNase I (Thermo Fisher Scientific) 
• Superscript III Reverse Transcriptase (Thermo Fisher Scientific) 








Table 2 The primer sequences for qRT-PCR 






Nuclear Factor 4 
5`-ATG GCT CTC CTG 
AGA GTG GA-3` 
5`-CAG CGC AAG ACC 
TAA TGA CA – 3` 
223 bp 60 
Albumin 
5`-GAA ACA TTC ACC 
TTC CAT GC-3` 
5`-ACA AAA GCT GCG 
AAA TCA TC-3` 
152 bp 60 
Alpha-fetoprotein 
5`-CAT ATG TCC CTC 
CTG CAT TC-3` 
5`-TTA AAC TCC CAA 
AGC AGC AC-3` 
272 bp 60 
Human Serpin 
peptidase inhibitor 
5`-ATG ATC TGA 
AGA GCG TCC TG-3` 
5`-AGC TTC AGT CCC 
TTT CTC GT-3` 
152 bp 60 
Peptidylprolyl 
isomerase A (PPIA) 
5`-TTC ATC TGC ACT 
GCC AAG AC-3` 
5`-TCG AGT TGT CCA 
CAG TCA GC-3` 




Table 3 Antibodies used for immunostaining. 
Antibody I/II Dilution Host and type Supplier  
Albumin  Primary 1:200 Mouse monoclonal R&D Systems 
α fetoprotein  Primary 1:200 Rabbit polyclonal DAKO 
α1- antitrypsin  Primary 1:200 Mouse monoclonal Novus Biologicals 
Hepatocyte nuclear 
factor 4α 
Primary 1:200 Rabbit monoclonal Abcam 
Cytokeratin 18 Primary 1:100 Mouse monoclonal Abcam 
MRP2 Primary 1:100 Rabbit monoclonal Abcam 
Goat anti-mouse 
conjugated with Alexa 
Fluor 568  
Secondary 1:1000 Goat polyclonal ThermoFisher 
Scientific 
Goat anti-rabbit 
conjugated with Alexa 
Fluor 488 







4.1. Cell biology 
 
4.1.1. Derivation and culture of primary human foreskin fibroblasts 
 
The foreskin samples were obtained from the private clinic (Pediatric and Ambulatory 
Surgery, Elster Passage, Zschochersche Straße 48, 04229 Leipzig). The donor was a healthy 
6-year-old boy. The tissue was removed according to conventional aseptic techniques. The 
dissected skin was washed and disinfected. After overnight incubation in Diaspase II (Sigma-
Aldrich) 4 °C, the epidermis was removed. The remaining skin was cut with a scalpel to 
micrometers pieces. Skin pieces were then plated on culture dish and explant fibroblast 
cultures were maintained at 37 °C in 5% CO2 in Dulbecco's Modified Eagle's Medium 
(DMEM, LifeTechnologies) low glucose, supplemented with 20% fetal bovine serum (FBS, 
LifeTechnologies) and penicillin (100 U/mL)-streptomycin (100 μg/mL). 
 
4.1.2. Counting cells 
 
The cells were counted using Neubauer chamber. To loading groove, 10µl of sample diluted 
with trypan blue dye was added. The counting was performed using 10x objective. Cells 
which were not blue were counted in the few squares. The concentration was calculated using 
this formula: 
Concentration = (Number of Cells x 10.000)/ (Number of square x dilution). 
 
4.1.3. Cryo-preservation of cells 
 
To prepare cells for cryostorage, confluent cultures were detached using Versene (iPSCs) or 
trypsin/EDTA solution and centrifuged at 900g for a period of 5 minutes. The supernatant was 
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aspirated, and cells were re-suspended in the cryogenic medium. For fibroblast, cryogenic 
medium contained 45% DMEM, 45%FBS and 10 % dimethyl sulfoxide (DMSO). Pluripotent 
stem cells were cryopreserved in 90% of Essential 8 medium containing 10% of DMSO. Cell 
suspensions transferred to cryogenic vials were prepared for liquid nitrogen storage by 
incubation in -80°C freezer overnight in Mr. Frosty™ freezing container. 
 
4.1.4. Thawing of cryo-preserved cells 
 
The cryostored cells were recovered from storage by thawing in a 37ºC for 5 min. To remove 
residual cryogenic medium prior to culture, the contents of each vial were transferred to 15 
mL Falcon® tubes containing culture medium and centrifuged at 900g for 5 minutes. The cell 
viability was measured after thawing using the Trypan blue exclusion assay and cells were 
seeded into culture vessels or flasks in adequate density.  
 
4.1.5. Cell reprogramming 
 
The foreskin fibroblasts were thawed and expanded in DMEM medium low glucose with 10% 
ESC qualified FBS (Life Technologies). The cells were transfected with episomal vectors 
containing reprogramming factors: human Oct4, Sox2, Klf4, L-myc, Lin28, shRNA-p53, 
miR302/367 cluster and GFP (System Biosciences). For transfections, Lipofectamine 3000 
(Life Technologies) was used according to manufacturer's protocol. The cells in passage 
number 4 were seeded into the Geltrex-coated 6-well plate (Life Technologies) one day 
before transfection. The plasmids DNA-lipid complexes were prepared in OptiMEM medium 
(Thermo Fisher Scientific) and added dropwise to the cells. On the following day, the medium 
was changed and on the third day the second transfection was performed. The medium was 
changed daily. The fibroblast medium was changed to Essential 8 (E8, Life Technologies) 15 
days after transfection. Colonies were picked up mechanically on day 24 and plated in 
separate wells on Geltrex-coated 24-well plate. After 5 days, the best iPS cell line was chosen 
for future expansion. There was no GFP expression in the cells 30 days after plasmid 
transfection. The cells were routinely split using Versene (LifeTechnologies) in feeder-free 
conditions in the presence of Essential 8 medium. 
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4.1.6. Cultivation and expansion of iPSCs 
 
The induced pluripotent stem cells were cultured in Essential 8 medium (ThermoFisher 
Scientific) on the 6-well plates coated with Geltrex (ThermoFisher Scientific) at the 
concentration of 0,12–0,18 mg/mL. Every 4-5 days cells were split using Versene 




For immunostaining, cells were fixed for 15 min at room temperature (RT) in 4% 
Paraformaldehyde solution Roti-Histofi (Carl Roth GmbH + Co. KG), then washed three 
times in PBS (LifeTechnologies), and blocked and permeabilized for 1 h in PBS with 1% 
Fetal Bovine Serum (Sigma-Aldrich) and 0,1% of Saponin (Sigma-Aldrich). Cells were then 
incubated with primary antibodies overnight at 4 °C, rinsed three times with PBS, and 
incubated with secondary antibodies for 1 hour at RT. DAPI was used as a nuclear 
counterstain (Thermo Scientific). Antibodies used for characterisation of iPS cells: Nanog 
(Cell Signaling 4903 rabbit monoclonal IgG), Oct4 (Cell Signaling 2840 rabbit monoclonal 
IgG), Sox2 (Cell Signaling 3579 rabbit monoclonal IgG), SSEA4 (Thermo Scientific MA1-21 
mouse monoclonal IGG), Claudin6 (R&D Systems MAB3656 mouse monoclonal IGG). 
Antibodies used for characterisation of hepatic-like cells Alpha Fetoprotein (Dako A 0008, 
rabbit polyclonal), HNF4a (Abcam ab92378, rabbit monoclonal), Albumin (R&D Systems 
mab14-55, mouse monoclonal), Cytokeratin 18 (Abcam ab82254, mouse monoclonal), 
MRP2. Alexa Flour 488 conjugated antibody goat anti-rabbit and Alexa Fluor 633 conjugated 
antibody goat anti-mouse (Thermo Scientific) were used as secondary antibodies. 
 
4.3. In vitro spontaneous differentiation 
 
The iPSCs colonies were detached from the plate using Versene (LifeTechnologies) and 
suspended in Essential 6 medium (LifeTechnologies). The cell aggregates were cultured in 
suspension on low attachment Petri dishes to generate embryoid bodies. After 7 days, 
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embryoid bodies were transferred to Geltrex-coated 6-well plates and cultured for another 14 
days. Afterwards, cells were stained (as described before) for markers for neurons 
(Neurofilament heavy Novus Bio NB300-135, rabbit polyclonal) and muscle cells (Alpha-
Smooth muscle actin Sigma A5228, mouse monoclonal). 
 
4.4. Karyotype analysis 
 
Chromosomal analysis was performed after GTG-banding by Dr. Heidrun Holland (Team 
Leader, Authentication, Stability, and Identity of Cells, SIKT and Faculty of Medicine 
Leipzig University, Philipp- Rosenthal Str. 55, Leipzig, Germany). Seventeen metaphases 
were counted and three karyograms analysed with no evidence of numerical or structural 
chromosomal aberrations. 
 
4.5. RNA isolation 
 
The total RNA was isolated from cells at day 24 of hepatic differentiation protocol using 
RNeasy Mini Kit (Qiagen). Briefly, cells were lysed and homogenised using lysis buffer after 
washing with PBS. Then ethanol was added according to protocol and sample was loaded 
onto the RNeasy silica membrane column. Purification of contaminants was performed by 
washing with provided buffers and spinning the column. Pure, concentrated RNA was eluted 
by washing with 50 µl of DNaze free water. RNA concentration and quality were measured 
by ND1000 Spectrophotometer (NanoDrop). Isolated RNA was stored at -80°C. 
 
4.6. Quantitative PCR 
 
The gene expression of hepatocyte-specific proteins (Protein phosphatase 1 - PP1, Hepatocyte 
Nuclear Factor 4 alpha - HNF4a, Albumin - ALB, Alpha-fetoprotein - AFP, Human Serpin 
peptidase inhibitor - A1AT were validated using qPCR. Isolated RNA was reverse transcribed 
using Superscript III Reverse Transcriptase (Thermo Fisher Scientific) according to 
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manufacturer protocol. The expression of target mRNAs was quantified using Applied 
Biosystems 7500 Real-Time PCR System with CYBR Green PCR master mix. Each reaction 
was performed in triplicate in conditions: 95°C 5min followed by 40 cycles of 95°C for 15s 
denaturation, 60°C 15s annealing and 72°C for 30s extension. Protein phosphatase 1 (PP1) 
gene was the endogenous control. The Ct value was normalised against endogenous control to 
obtain ∆Ct. Fold difference was calculated using2-∆∆ Ct method. The following primers were 
used: Human Hepatocyte Nuclear Factor 4 (HNF4α) F 5`-ATG GCT CTC CTG AGA GTG 
GA-3`, R 5`-CAG CGC AAG ACC TAA TGA CA – 3`, Albumin (Alb) F 5`-GAA ACA TTC 
ACC TTC CAT GC-3’, R 5`-ACA AAA GCT GCG AAA TCA TC-3`, Alpha-fetoprotein 
(AFP) F 5`-CAT ATG TCC CTC CTG CAT TC-3`, R 5`-TTA AAC TCC CAA AGC AGC 
AC-3`, Human Serpin peptidase inhibitor (A1AT) F 5`-ATG ATC TGA AGA GCG TCC TG-
3`, R 5`-AGC TTC AGT CCC TTT CTC GT-3`, PP1 F 5`-TTC ATC TGC ACT GCC AAG 
AC-3`, R 5`-TCG AGT TGT CCA CAG TCA GC-3`. 
 
4.7. Periodic acid-schiff (PAS) staining 
 
The cells at day 24 of differentiation were stained using Periodic Acid-Schift (PAS) staining 
system (Sigma-Aldrich) according to the manufacturer’s instruction. Briefly, cells were first 
fixed with Formalin-Ethanol Fixative Solution then washed with water. Next cells were 
incubated 5 min in Periodic Acid Solution followed with distilled water washing. Then cells 
were immersed in Schiff’s Reagent for 15 min. After washing with water, nucleuses were 
counterstain with hematoxylin and analysed. 
 
4.8. Indocyanine green uptake and release 
 
Indocyanine green (ICG, Cardiogreen, Sigma-Aldrich) was dissolved in DMSO (Sigma-
Aldrich) and then added to the medium for 1 h. The final concentration of the resulting ICG 
solution was 1 mg/ml. After incubation medium was exchanged and images representing ICG 
uptake was taken with the microscope. After 6h, functional ability of hepatocytes to remove 
the dye was inspected again with the microscope.  
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4.9. Plasmid transfection 
 
The plasmid was detailed described in the previous section. The transfection was done using 
Lipofectamine 3000 (Invitrogen). Before transfection, 1 mg plasmid and 2 mL Lipofectamine 
3000 separately was diluted with 50 mL serum-free Opti-MEM I (Invitrogen) and incubated 
for 5 min. Then, solutions were mixed and incubated additionally for 20 min at room 
temperature. After incubation mixture was added to the medium and mixed gently. The 
medium was replaced with a new culture medium after 24h. 
 
4.10. Hepatic differentiation 
 
For the hepatic differentiation, the previously described protocol was used (Yu et al., 2012). 
Briefly, when cells reach 70% confluency medium was changed for RPMI1640 media 
containing B27 Supplements Minus Insulin (Invitrogen), 100 ng/mL Activin A (R&D 
Systems), 20 ng/ml fibroblast growth factor 2 (FGF2) (R&D Systems) and 10 ng/ml bone 
morphogenetic protein 4 (BMP4) (Peprotech) to induce endoderm. After 8 days of the culture, 
dishes were moved to hypoxia (4%O2) in RPMI/B27 Supplements (Invitrogen) medium with 
20 ng/mL BMP4 and 10 ng/mL FGF2 for 5 days. Next medium was changed to RPMI/B27 
supplemented with 20 ng/mL hepatocyte growth factor (HGF, Peprotech) for additional 5 
days in hypoxia. The final stage of differentiation was in HCM™ hepatocyte culture medium 
(Lonza, but omitting the EGF) supplemented with 20 ng/mL Oncostatin M (R&D Systems) 
for 5 days in normoxia (21%O2). The medium was prepared freshly and changed daily. 
 
4.11. Wheat Germ Agglutinin staining 
 
Wheat Germ Agglutinin (WGA), Alexa Fluor® 488 Conjugate can be used to visualise cell 
membrane in the fluorescent microscope. WGA binds to sialic acid and N-acetylglucosaminyl 
residues in the cell membrane and in combination with fluorochrome can be easily detected. 
Staining was performed according to manufacturer protocol, briefly, WGA conjugate stock 
solution was dissolved in medium to the concentration of 5.0 μg/mL. The cells were 
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incubated with the mixture for 10 min at 37°C. Then cells were counterstain with DAPI and 
fixed with 4% paraformaldehyde for 15 min prior to secure the sample during transport to the 
confocal microscope.  
 
4.12. Validation of hepatic differentiation efficiency 
 
To validate the efficiency, cells were cultured on two wells slides (Thermo Fisher Scientific 
Inc) and after the hepatic differentiation, stained as described above for HNF4a and ALB. 
Whole slides were scanned (Bioquant, University Heidelberg), and using image analysis tool 
ImageJ (Schnider), area of double-positive cells was measured.  Scans of four wells were 
analysed per condition.  
 
4.13. RNA isolation and sequencing 
 
The total RNA, including short RNAs, was purified from frozen hepatocytes (pooled 10 
donors HMCS10, GIBCO) and cells at day 20 and 24 of hepatic differentiation using the 
miRNeasy Micro Kit (Qiagen) and quantified by Nanodrop spectrophotometer. The total 
RNA was used in the small RNA protocol with the TruSeq™ Small RNA sample prepkit v2 
(Illumina) according to the instructions of the manufacturer. The barcoded libraries were size 
restricted between 140 and 165bp, purified and quantified using the Library Quantification 
Kit - Illumina/Universal (KAPA Biosystems) according to the instructions of the 
manufacturer. Sequencing was performed with an IlluminaHighScan-SQ sequencer at the 
sequencing core facility of the IZKF Leipzig (Faculty of Medicine, University Leipzig). 
Hepatic-like cells were cultured and harvested at two different time points: day 20 of hepatic 






4.14. Bioinformatic Analysis 
 
4.14.1.  Sequencing quality and mapping 
 
The raw reads were analysed with fastqc for a quality control of the sequencing. Reads were 
trimmed from adapters and prepared for mapping to the human genome assembly hg38. 
Mapping was performed with segemehl (Hoffmann et al., 2009), which allows multiple read 
mapping. Subsequently, the mapped reads were overlapped with gene annotation GENCODE 
v24 and RepeatMasker track (retrieved from UCSC) using rnacounter and bedtools (Quinlan, 
2014), respectively. Additionally, human snoRNA annotations were taken from literature 
(Jorjani et al., 2016). 
 
4.14.2. Analysis of differential expressed ncRNAs  
 
The count data were normalized and differentially expressed miRNAs and snoRNAs genes 
were identified using EdgeR a Bioconductor software package for every group pairwise 
comparison (Robinson et al., 2010). The differentially expressed miRNAs and snoRNAs were 
selected by a false discovery rate (FDR) less than 0.001 and sorted by the adjusted fold 
change (including only genes with normalised fold change higher than 2). 
 
4.14.3.  Target pathways prediction of differentially expressed miRNAs  
 
In order to identify predicted targets of the differentially expressed miRNAs, the DIANA 
mirPath tool V3.0 was used.  This online tool allows detecting KEGG pathways by mapping 
target genes. For every comparison, up to 50 significant miRNAs were analysed. DIANA-
TarBase v7.0 was used to analyse gene interactions. This database contains more than half a 
million miRNA-gene interactions. The advantage of this database is also that every interaction 
is experimentally validated, which makes it the most relevant in the field.  Fisher’s exact test 




4.14.4. Identification of novel ncRNAs candidates 
 
The obtained expression signals identified in all samples (HLCs day 20, HLCs day 24 and 
hepatocytes) were within a certain distance were transformed to loci. Next, loci were labeled 
by the type of transcript and only not annotated loci remained on the list for future analysis. 
Loci overlapping with Nuclear insertions of mitochondrial sequences (NuMTs) were 
removed. The NuMTs track available for the human hg19 assembly at UCSC Table Browser 
was mapped to hg38 using liftOver and intersected with the loci. Then tRNAScan (Schattner, 
Brooks, & Lowe, 2005) was applied to recognize and remove loci coding for transfer RNA. 
To identify novel snoRNA candidates in the remaining loci, snoReport (Hertel, Hofacker, & 
Stadler, 2008) or RNAz 2.0 (Gruber, Findeiß, Washietl, Hofacker, & Stadler, 2010) was used. 
For each remaining locus, the conservation was checked by searching for homologous 
sequences in other deuterostomes species using blast (Altschul, Gish, Miller, Myers, & 
Lipman, 1990) with settings: E-value: 1e-3, minimal base identity: 50%, minimal score: 60 
and minimal length of query: 50%. Found homologous were used as queries in the subsequent 
blast search in the next species. Repetitive loci (having more than 100 accepted blast hits in a 
species) were rejected from the further comparative analysis. Alignments containing all found 
homologous sequences were computed with MUSCLE (Edgar, 2004). Consensus secondary 
structures were computed using RNAlifold (Bernhart, Hofacker, Will, Gruber, & Stadler, 
2008) under emacs RALEE mode (Griffiths-Jones, 2005). To identify snoRNA sequences that 
have not been recognised by snoReport, first putative box motifs were identified using 
position weight matrices of the snoRNA boxes C, D, C', D', H, and ACA constructed from all 
annotated human snoRNAs (Jorjani et al., 2016). If a sequence harbors motifs C and D, or H 
and HACA in correct order and distance, the sequence was next checked for its ability to fold 
into the typical snoRNA secondary structure using RNAfold (Bernhart, Hofacker, Will, 
Gruber, & Stadler, 2008). For sequences identified as putative snoRNAs in this manner, 










5.1. Generation of iPSCs using episomal vectors 
 
To generate a new iPSCs line, non-viral and non-integrating episomal vectors were used. To 
make transfection easy and accessible, a lipotransfection agent was applied. This method is 
commonly practiced worldwide in order to transfect many types of cells. Plasmids 
oriP/EBNA1 (Epstein–Barr nuclear antigen-1)-based episomal vectors (Yu et al., 2009) were 
purchased from System Biosciences. The plasmid expression system contains well-known 
genes for reprogramming: transcription factors – Oct4, Sox2, Klf4, L-myc, Lin28. This, 
together with a cluster of miRNA – miR302/367, which can reprogram cells alone, and 
shRNA-p53 for the inhibition of potential reprogramming caused apoptosis. This system is 
also provided with the reporter gene GFP to allow for the fast and non-invasive verification of 
transfection efficiency. This system supports reprogramming with 0,1 % efficiency when 30% 
of cells were positive for GFP.  
 
5.1.1. Cell transfection 
 
Human fibroblasts isolated from a 6-year-old boy were transfected in order to obtain a new 
iPSCs line (Fig.6). Cells were divided into three groups: transfected 1, 2, or 3 times (every 
second day). Plasmids for transfection contains a GFP gene that allows tracking the efficiency 
and plasmid degradation. Therefore, cells after lipotransfection were inspected for 
fluorescence marker expression. Representative images of the transfected cells are shown 
from day 7 and 14 of reprogramming (Fig. 7.A and 7.B). The efficiency of transfection was 
estimated at 30% of initial seeding density. During the process of reprogramming, cells 























Figure 6 Morphology of fibroblasts on day 0 of reprogramming.    
Figure 7 Transfection of fibroblasts with episomal vectors – efficiency on day A) 7 and 
B) 14.  
Left image: GFP positive cells in green; right image: bright field image of the culture in the 
same spot. Pictures are representative of three experiments. 
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5.1.2. Establishment of iPSCs line 
 
15 days after the first transfection, the medium was changed to the one suitable for pluripotent 
stem cells. The first iPSCs colonies appeared on day 21 (Fig. 8). They were easily 
distinguishable from the surrounding fibroblasts. On day 24, colonies were manually picked 
up and placed into a Geltrex-coated 96 wells plate, based on their morphology. The high 
quality iPSCs displayed colonies with defined borders that were densely packed with small 
round cells containing a large nuclei and tight intercellular contacts. Every colony was 
transferred into a separate well for clonal expansion. After 5 days in the culture, the best 
clones were selected and passaged for further expansion (Fig. 9). The clone selected for 
characterisation was derived from a group of fibroblasts transfected two times. The new 
iPSCs line resembled the morphology of embryonal stem cells. The GFP expression was 
constantly inspected in order to track the presence of the vectors. After 30 days from the first 
transfection, there was no evidence of GFP expression. Cells after passage 4 could be 
successfully frozen and thawed without morphological changes, which affirm pluripotency of 
these cells (Fig. 10).  
 
 
Figure 8 iPSCs appearing colonies on day 21 (left) and 23 (right).  
Original magnification x100, representative images of three experiments. 
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Representative images of clone chosen for expansion. 
 
 
Figure 10 Morphology of iPSCs in the culture after cryopreservation. 
Pictures are representative of three independent experiments. 
5.2. Pluripotency characterisation of the iPSCs 
 
5.2.1. Pluripotency markers 
 
To confirm the expression of pluripotency markers in newly obtained iPSCs, cells were 
immunostained with the antibodies against Oct4, Nanog, Sox2, SSEA4 and Claudin6. Cells 
were separately stained with antibodies or as a double staining of cells at a different passage 
number. A commercial iPSCs line was used as a positive control. The negative control was 
Figure 9 iPSCs colony chosen for future expansion. 
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parental fibroblasts. The results of immunostaining showed the expression of pluripotency 
markers in iPSCs colonies (Fig. 11). 
 
 
Figure 11 Immunostaining of iPSCs showing expression of pluripotency markers: 
OCT4, SOX2, NANOG, SSEA4 and Claudin6 (Skrzypczyk et al., 2016). 
Pictures are representative of five independent experiments. 
 
5.2.2. Spontaneous differentiation assay 
 
In order to demonstrate the in vitro differentiation potential of newly generated iPSCs, 
spontaneous differentiation assay was performed. First, embryoid bodies were created by 
culturing cells in suspension without bFGF and TGFβ (Fig.12). Next, cells were maturated by 
culturing them on Geltrex-coated plates. Using in vitro studies, iPSCs have been shown to 
differentiate into every germ lineage that includes neurons and muscle cells (Fig.13). This, 
together with results of directed differentiation into hepatocytes, prove a pluripotent character 
of newly generated iPSCs. 
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Pictures are representative of three independent experiments. 
 
 
Figure 13 Differentiation potential of iPSCs (Skrzypczyk et al., 2016). 
Immunocytochemical staining of in vitro spontaneous differentiation: Neurofilament heavy 
(NFH), smooth muscle actin (αSMA), DAPI for nucleic acid stain. Original magnification 










To determine if chromosomal aberrations occurred during the reprogramming process, GTG-
banding analysis was performed. The analysis was done by Dr. Heidrun Holland (Team 
Leader, Authentication, Stability, and Identity of Cells, SIKT and Faculty of Medicine at 
Leipzig University, Philipp- Rosenthal Str. 55, Leipzig, Germany). Seventeen metaphases 
were counted and three karyograms were analysed with no evidence of numerical or structural 







Figure 14 Karyogram of the iPSCs passage number 20 (Skrzypczyk et al., 2016). 
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5.3. Hepatic differentiation of iPSCs and HLCs characterisation 
 
5.3.1. iPSCs hepatic differentiation 
 
Controlled generation of hepatocytes in vitro is a crucial step in the advancement of iPSCs 
research from the laboratory to its clinical application. However, the molecular mechanisms 
that regulate the expression of mature liver genes remain a central challenge. Since the liver is 
responsible for detoxification, there is a priority to obtain cells that are capable of acquiring 
those functions.  
In order to differentiate iPSCs into HLCs, cells were seeded into Geltrex-coated 6 well plates. 
The medium with cytokines was changed daily, according to the protocol (Yu et al. 2012). 
The differentiation of a commercial line and a new cell line proceeded similarly. During 
differentiation, stem cell morphology gradually changed towards the polygonal shape of 
hepatocytes. After 22 days of differentiation, it was possible to observe binucleated cells and 
the accumulation of lipid droplets (Fig. 15). To obtain images of cell shape, 3D confocal 
microscopy imaging was applied. The cells were stained with WGA AF488-conjugated to 
visualise the cell membrane (Fig. 16).  
 
 
Figure 15 Morphology of HLCs obtained from differentiation of new iPSCs. 




Figure 16 VEGEA confocal staining of HLCs shape. 
Hepatic differentiation of commercial iPSCs. Nucleuses stained with DAPI. Magnification 
400x. Pictures are representative of three independent experiments. 
 
5.3.2. Expression of hepatic markers 
 
To confirm the expression of hepatic markers in obtained HLCs, cells were immunostained 
with the antibodies against HNF4a, ALB, CK18, MRP2, and the fetal marker AFP. Hepatic 
marker MRP2 was detected in cells, but only locally. The HepG2 cell line was used as a 
positive control and fibroblasts as a negative. Cells were stained separately or with a double 
staining with specific antibodies. The results of immunostaining showed the expression of 
mature hepatic markers and the fetal marker AFP (Fig. 17). 
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Pictures are representative of three independent experiments. 
Figure 17 Expression of hepatic markers in new iPSCs-derived HLC: HNF4a, ALB, AFP, 




5.3.3. Hepatic gene expression in HLCs 
 
In order to confirm successful differentiation, the expression of hepatic genes was quantified 
using q-PCR. The RNA isolated from HLCs day 24, HepG2 cell line, frozen hepatocytes, and 
iPSCs were used for q-PCR. The results demonstrated that hepatocytes have the highest 
expression of mature hepatic genes: A1AT, HNF4a, and Albumin, as suspected (Fig. 18). 
HepG2 cells expressed mature hepatic genes, but in a lower level than in hepatocytes and they 
also expressed AFP. Tested HLCs expressed mature hepatic genes, but at a much lower level 
than hepatocytes. Additionally, HLCs had a high expression of fetal liver marker AFP. In a 
negative control for hepatic genes – iPSCs there is a lack of expression of those genes, which 




Figure 18 Quantitation of hepatic genes: AFP, A1AT, HNF4a, Albumin mRNA levels 
by qPCR analysis in HLCs, HepG2, hepatocytes and iPSCs.  
Data shown are from three separate experiments and are normalized to PP1 gene expression; 
without significant changes between HLCs and HepG2 or hepatocytes. 
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5.3.4. Hepatic functions in HLCs 
 
To show that cells after differentiation have a specific hepatocytes functions, PAS staining 
and ICG metabolism testing were done. The glycogen serves as a buffer to maintain blood-
glucose levels in the body. In a functional liver, the concentration of glycogen is 10% of its 
weight. The glycogen forms granules in the cytosol of hepatocytes and can be detected by 
PAS staining (Berg, Tymoczko, & Stryer, 2002). The results of PAS staining in HLCs are 
shown on Figure 19. The obtained HLCs had a purple-red colour, which indicates glycogen 
presence in cytosol.  
 
 
Figure 19 Representative images of PAS staining to detect glycogen storage in HLCs. 
 Glycogen in purple-red colour, nuclei stained by haematoxylin – dark blue. Pictures are 
representative of three independent experiments. 
  
An important function of hepatocytes is detoxification. ICG testing is widely used to assess 
the in vitro function of iPSCs-derived HLCs. ICG is taken up exclusively by hepatocytes via 
the transporter organic anion transport protein OATP-C, which is also known as SLCO1B1 
(Solute carrier organic anion transporter family member 1B1). This transporter is located in 
the basolateral membrane of hepatocytes. ICG is then actively excreted into the bile canaliculi 
by MRP2. The results showed that HLCs were turning green after incubation with ICG. After 
6 hours, the ICG was released by the cells (Fig. 20). The green colour loss in the cells and the 





Figure 20 Representative images of ICG assay. 
ICG uptake (left) and release in HLCs after 6h (right). Pictures are representative of three 
independent experiments. 
 
5.4. HNF4a overexpression during differentiation  
 
5.4.1. Cell transfection during differentiation 
 
Commercial iPSCs were differentiated, as previously described, into HLCs. On day 7 of 
differentiation, using a lipotransfection agent, cells were transfected with a plasmid that 
contained human HNF4a gene. There was no evidence for cell cytotoxicity after transfection. 
The cells were immunostained with the antibodies against HNF4a and Albumin (Fig. 21). The 
results showed that the transfection with plasmid containing an open reading frame for the 
HNF4a gene, indeed caused overexpression of this transcriptional factor. The overexpression 




Figure 21 Overexpression of HNF4a after transfection in cells during differentiation. 
Non-nuclear localisation spots. Left image - cells 48h after transfection, fluorescent 
microscope; right image – cells after 24 days of differentiation from confocal microscope, 
magnification x200. Pictures are representative of three independent experiments. 
 
5.4.2. Comparison of hepatic differentiation efficiency 
 
The cells during differentiation with a modified protocol behaved as previously described. 
Their morphology was typical for HLCs and there were no visible differences when compared 
to HLCs obtained with an unmodified protocol. HLCs obtained from a protocol with HNF4a 
overexpression were immunostained for hepatic markers as before. Results showed an 
expression of mature hepatic markers (HNF4a, Albumin, CK18), but also the fetal liver 
marker AFP (Fig. 22). Obtained HLCs were able to store glycogen and metabolise ICG, 
which indicates that those cells have hepatic functions (Fig. 23). There were no visible 
differences between standard protocol and with HNF4a overexpression in the hepatic marker 
expression and functions. 
To compare protocols based on hepatic gene expression, q-PCR of RNA isolated from HLCs 
with overexpression was performed (Fig. 24). The results showed that protocol with plasmid 
transfection produced HLCs with lower hepatic gene expression, which can indicate that 





Figure 22 Expression of hepatic markers in HLCs obtained with HNF4a overexpression. 
HNF4a and ALB confocal image magnification x200; AFP, CK18 fluorescence microscope 




Figure 23 Representative images of hepatic functions in HLCs obtained with 
overexpression of HNF4a; A) PAS staining, B) ICG uptake; C) ICG release after 6h.  
Glycogen in purple-red colour, nucleuses stained by haematoxylin – dark blue. Green colour 
in cells indicates ICG metabolism. Pictures are representative of three independent 
experiments. 
 




Figure 24 Comparison of the hepatic differentiation protocols by qPCR results. 
Hepatic gene expression in HLCs; results from three independent experiments, without 
significant changes. 
 
5.4.3. Whole slide scanning  
 
To evaluate the efficiency of differentiation by using different protocols, the entire slides with 
cells were scanned to create virtual slides. To detect truly differentiated HLCs, cells were first 
differentiated inside slides and then stained for the presence of mature hepatic markers: 
HNF4a and Albumin. Slides were then scanned to visualise areas of double positive cells for 
hepatic markers. The virtual slides were created in collaboration with Heidelberg University 
(Fig. 25). Using an image analysis, the area of double positive HLCs were calculated and 
compared after two protocols (Fig. 26). The results indicate that the efficiency of hepatic 
differentiation was 30% of the area of cultivated cells. However, the AFP positive cells cover 
the slide in almost 90% of the area (visual observations, data not shown). Protocol with 
HNF4a overexpression produced comparable numbers of HLCs which demonstrates that this 





Figure 25 Representative virtual slide.  
The whole area of one well from each of slides/protocols as a virtual slide; separate pictures 
with magnification x400 were combined to create virtual slide in order to calculate efficiency 
of the whole differentiation area; chromatin DAPI – blue, Albumin – red, HNF4a – green.  
 
 
Figure 26 Image analysis of slides after scanning.  
Percent of the area with colocalization of HNF4a and Alb expression in HLCs (two wells 




5.5. Non-coding RNA analysis  
 
5.5.1. Non-coding RNA sequencing quality 
 
The quality of sequencing was analysed by FastQC software (chapter 4.14.1). In brief, there 
were no deviations from the standard Illumina sequencing. The RNA sequencing resulted in 
reads between 8.3 M and 25.2 M. 73% to 80% of the reads were longer than 17 nucleotides 
after adapter clipping. Most of the obtained clipped sequences (92% to 94%) were 
successfully mapped (Fig. 27). Between 345k and 1.45 M reads were identified as miRNA, 
while as snoRNA – between 4.14 M and 11.9 M reads (Fig. 28). Around 15% of the reads that 
were identified as a snoRNA contained adapter sequences. Those reads were up to 20 nt long 
(referred as short snoRNA reads). Among the sequenced reads, other types of transcripts were 
identified, including rRNA (between 6.5% and 16.5%), snRNA, long intergenic noncoding 




Figure 27 Total number of sequenced reads, reads after clipping and mapped reads.  
“All” symbolised all reads obtained after sequencing. The bar showing clipped reads contains 
reads that could be processed by cutting the helper sequences. Mapped reads bar show reads 
aligned to a reference genome. Clipped and mapped reads are divided into reads containing an 
adapter (length below 50 nt) and reads that do not contain an adapter (length >=50 nt). 
HLCd20, HLCd24 shows reads from HLCs day 20 and day 24 of differentiation respectively, 




Figure 28 Percentage of mapped reads with an adapter.  
Mapped reads of miRNA and snoRNA are divided into reads containing an adapter (length 
below 50 nt) and reads that do not contain an adapter (length >=50 nt). HLCd20, HLCd24 
shows reads from HLCs day 20 and day 24 of differentiation respectively, in comparison to 




Figure 29 Percentage of different transcript types in the sequencing. 
Identified ncRNA without miRNAs and snoRNAs transcripts which were successfully 
mapped and overlapped genome annotations. HLCd20, HLCd24 shows transcripts from 
HLCs day 20 and day 24 of differentiation respectively, in comparison to transcripts from 
hepatocytes (Skrzypczyk et al., 2017, manuscript in preparation). 
 
To visualize the consistency between replicates and global changes between the studied 
samples, a hierarchical clustering of all detected ncRNA was performed (Fig.30). This 
revealed a strong separation between the hepatocytes and hepatic-like cells, and good 





Figure 30 Cluster heat map of gene expression data.  
Hierarchical clustering was generated using Euclidean measure to obtain a distance matrix 
and correlation coefficients of log2- transformed expression values. The colour scale indicates 
the degree of correlation (white, low correlation; red, high correlation, see legend). 
 
5.5.2. MicroRNA analysis 
 
First, hepatic specific miRNA genes (from literature) were investigated. MiR-122-5p, miR-
27b-3p, miR-23b-3p, miR-148-3p, miR-146b-5p and miR-194-5b were upregulated in 
hepatocytes, however their expression in the HLCs was decreased (Fig. 31). Nevertheless, 
upregulation of a mature hepatic miRNAs in HLCs on day 24 shows hepatic linage 
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commitment during differentiation.  The miRNAs which had elevated expression in the HLCs 
on day 24 were reported to be specific for fetal hepatocytes: miR-23a-3p, miR-30a-5p, 
miR483-3p, miR-92b-3p (Fig. 32). Upregulation of the fetal liver miRNAs and lower 
expression of the mature liver miRNAs in HLCs shows that differentiated cells resemble a 
fetal characteristic, as previously described. Remarkably, a several upregulated miRNAs at 
the end of differentiation (day 24) indicate an epithelial phenotype of HLCs. Those miRNAs, 
previously described as blocking EMT, were plotted separately: EMT related (miR-200c-3p 
miR-200b-3p, miR-204-5p, miR-199b-3p, miR-199a-3p and miR-429, Fig. 33). The selected 
miRNAs: miR-21-3p, miR-21-5p, miR-214, miR-216a, were also highlighted (Fig. 34). 
Expression of those miRNAs has been previously shown to increase during the last stage of 
hepatic differentiation of embryonic stem cells (ESC). Those miRNAs are connected to PI3K 
signalling and hepatic differentiation. 
 
Figure 31 Expression of hepatic specific miRNAs.  
MiR-122-5p, miR-27b-3p, miR-23b-3p, miR-148-3p, miR-146b-5p and miR-194-5b were 





Figure 32 Expression of fetal liver miRNAs.  
MiR-23a-3p, miR-30a-5p, miR483-3p, miR-92b-3p were upregulated in HLCs day 24 in 




Figure 33 Expression of miRNAs related to MET.  
MiR-200c-3p miR-200b-3p, miR-204-5p, miR-199b-3p, miR-199a-3p and miR-429 were 




Figure 34 Expression of PI3K related miRNAs shown to be upregulated during hepatic 
differentiation. 
MiR-21-3p, miR-21-5p, miR-214, miR-216a were upregulated in HLCs day 24 in comparison 
to hepatocytes and HLCs in day 20 of differentiation. 
 
The differentially expressed miRNAs between control hepatocytes and the different stages of 
differentiation (day 20, day 24) were identified. Those with adjusted low-p values (FDR) and 
with high fold changes at the same time are marked and visualized in the volcano plots (Fig. 
35, 36 and 37). MiRNAs expression changed during hepatic differentiation. Briefly, 14 
differentially expressed miRNAs with a threshold of FDR>0.05 were identified. 5 miRNAs 
were downregulated in HLCs day 24 including miR-367, miR-302, and also miR-516 in 
comparison to HLCs at day 20. 19 miRNAs were upregulated: miR-199a, miR-199b, miR-
211 and miR-214 in HLCs day 24 in comparison to HLCs at day 20. When compared to the 
hepatocytes, a greater number of miRNAs were differentially expressed. With a threshold of 
FDR<0.001 in the HLCs day 24, 228 miRNAs were downregulated when compared to the 
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hepatocytes, including miR-181d, miR-199a, miR-214, miR-200c, and miR-205. 88 miRNAs 
were upregulated in the hepatocytes including: let-7b-5p, miR-29c, let-7f-5p, let-7g-5p miR-
612, and miR-195, among others. 75% of the differentially expressed miRNAs in the 
hepatocytes compared with the HLCs day 24 were also differentially expressed in the 
hepatocytes compared with the HLCs day 20. Figure 38 presents a heatmap of the 100 most 
differentially expressed miRNAs for visualisation. A list of differentially expressed miRNAs 
is provided in the appendix. 
 
Figure 35 The volcano plot of differentially expressed miRNAs between HLCs day 20 
and HLCs day 24.  
The x-axis indicates a difference of expression level on a log scale, while the y-axis represents 
corresponding adjusted P values (FDR) on a negative log scale; statistically significant 
differences extends vertically. Red points indicate genes with the significance level of FDR> 




Figure 36 The volcano plot of differentially expressed miRNAs between HLCs day 20 
and Hepatocytes. 
The x-axis indicates a difference of expression level on a log scale, while the y-axis represents 
corresponding adjusted P values (FDR) on a negative log scale; statistically significant 
differences extends vertically. Red points indicate genes with the significance level of FDR> 




Figure 37 The volcano plot of differentially expressed miRNAs between HLCs day 24 
and Hepatocytes. 
The x-axis indicates a difference of expression level on a log scale, while the y-axis represents 
corresponding adjusted P values (FDR) on a negative log scale; statistically significant 
differences extends vertically. Red points indicate genes with the significance level of FDR> 




Figure 38 Heatmap showing the differentially expressed miRNAs.  
Differentially expressed miRNAs are represented in shades of blue (decreased expression) 
and red (increased) in HLCs day 20 (HLCd20), day 24 (HLCd24) and hepatocytes. 





To identify genes and pathways controlled by differentially expressed miRNAs, the DIANA-
miRPath v3.0 online tool was used (Vlachos et al., 2015). A posteriori approach (pathway 
union) was applied to increase the stringency of the prediction. The enrichment of the KEGG 
gene ontology terms related to differentially expressed miRNAs target genes is presented in 
Table 4. The differentially expressed miRNAs at HLCs day 20 in comparison to hepatocytes 
are related mostly to the signalling pathways regulating the pluripotency of stem cells, since 
they are miRNAs which induce pluripotency. The upregulated miRNAs in HLCs day 24 are 
involved in fatty acid biosynthesis, ECM-receptor interaction fatty acid metabolism, 
proteoglycans in cancer, the Hippo signalling pathway, steroid biosynthesis, and the adherens 
junction. Interestingly, the steroid biosynthesis pathway is special in this comparison. The 
differentially expressed enriched miRNAs from HLCs compared to hepatocytes additionally 
control lysine degradation, prion diseases, viral carcinogenesis, pathways in cancer, and the 
p53 signaling pathway. The HLCs d20 genes exclusively regulate 2 further pathways: 
microRNAs in cancer and the cell cycle. The pathway - transcriptional misregulation in 
cancer is unique for miRNAs from HLC d24 in comparison to hepatocytes. The hepatic 
upregulated miRNAs regulate pathways typical for those cells, like Hepatitis B, endodermal 
cell cancers, the PI3K-Akt signaling pathway, focal adhesion, TGF-beta signaling pathway, 
and also the Thyroid hormone signaling pathway. Intriguingly, the FoxO signaling pathway, 
protein processing in the endoplasmic reticulum, and endocytosis were restricted for the 
differentially expressed miRNAs in hepatocytes when compared with HLC d24. 
 
Table 4 Gene ontology categories of differentially expressed miRNAs targets (pathway 
union). 
Comparison  KEGG pathway p-value #genes #miRNAs 
Differentially 
expressed 
miRNAs in HLC 
d24 compared 
to HLC d20 
Fatty acid biosynthesis 
ECM-receptor interaction 
Fatty acid metabolism 
Proteoglycans in cancer 
Hippo signaling pathway 
Steroid biosynthesis 
Adherens junction 



























miRNAs in HLC 
d20 compared 
to HLC d24 
Lysine degradation 
Chronic myeloid leukemia 
Proteoglycans in cancer 
Wnt signaling pathway 


























Signaling pathways regulating 





















miRNAs in HLC 
d20 compared 
to hepatocytes 
Fatty acid biosynthesis 
ECM-receptor interaction 
Lysine degradation 
Proteoglycans in cancer 
MicroRNAs in cancer 
Adherens junction 
Fatty acid metabolism 
Hippo signaling pathway 
Prion diseases 
Viral carcinogenesis 
Pathways in cancer 
Cell cycle 
p53 signaling pathway 






















































Hippo signaling pathway 
Proteoglycans in cancer 
Pathways in cancer 
Adherens junction 
Hepatitis B 
Chronic myeloid leukemia 
Colorectal cancer 
Glioma 
Fatty acid metabolism 
p53 signaling pathway 
Small cell lung cancer 
Oocyte meiosis 
Thyroid hormone signaling pathway 
Steroid biosynthesis 
Prostate cancer 
PI3K-Akt signaling pathway 
Focal adhesion 












































































Fatty acid biosynthesis 
Fatty acid metabolism 































Pathways in cancer 
Lysine degradation 
Transcriptional misregulation in cancer 




























Pathways in cancer 
Hippo signaling pathway 
Proteoglycans in cancer 
Adherens junction 
Chronic myeloid leukemia 
Glioma 
Colorectal cancer 
p53 signaling pathway 
Oocyte meiosis 
Small cell lung cancer 
Thyroid hormone signaling pathway 
Prion diseases 
Steroid biosynthesis 
TGF-beta signaling pathway 
Prostate cancer 
Fatty acid metabolism 
PI3K-Akt signaling pathway 
































































































5.5.3. SnoRNA analysis 
 
In this study, expression of 18 non-canonical SNORD-like, and six candidate snoRNA genes 
reported in a study of Jorjani et al. was confirmed (Jorjani et al., 2016). Analogous to 
miRNAs, differentially expressed snoRNAs were identified. The volcano plots represent 
differentially expressed snoRNAs (Fig. 39, 40 and 41). A total of 77,6% of the differentially 
expressed snoRNAs in the hepatocytes compared with the HLCs day 20 were also 
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differentially expressed in the hepatocytes compared with the HLCs day 24. Among 210 
common differentially expressed snoRNAs were: SCARNA17, SNORD118, SNORA46, 
SNORA60 and SNORA81. With selected FDR, only 29 snoRNAs were differentially 
expressed between HLCs day 20 and day 24, including SNORA38, SNORA101B, 
SNORA38B. The differentially expressed snoRNAs are visualized in a heatmap (Fig. 42). Of 
those, 68% were box C/D snoRNAs, which is 44% of all box C/D snoRNAs. A list of all 
differentially expressed snoRNAs is provided in the appendix.  
 
Figure 39  The volcano plot of differentially expressed snoRNAs between HLCs day 20 
and HLCs day 24. 
The x-axis indicates difference of expression level on a log scale, while the y-axis represents 
corresponding adjusted P values (FDR) on a negative log scale; statistically significant 
differences extends vertically. Red points indicate genes with the significance level of FDR> 
0.001. Blue points represent SNORD114. Labels are given for the most significant 





Figure 40 The volcano plot of differentially expressed snoRNAs between HLCs day 20 
and Hepatocytes. 
The x-axis indicates difference of expression level on a log scale, while the y-axis represents 
corresponding adjusted P values (FDR) on a negative log scale; statistically significant 
differences extends vertically. Red points indicate genes with the significance level of FDR> 
0.001. Blue points represent SNORD114. Labels are given for the most significant 




Figure 41 The volcano plot of differentially expressed snoRNAs between HLCs day 24 
and Hepatocytes. 
The x-axis indicates difference of expression level on a log scale, while the y-axis represents 
corresponding adjusted P values (FDR) on a negative log scale; statistically significant 
differences extends vertically. Red points indicate genes with the significance level of FDR> 
0.001. Blue points represent SNORD114. Labels are given for the most significant 




Figure 42 Heatmap showing the differentially expressed snoRNAs. 
Differentially expressed snoRNAs are represented in shades of blue (decreased expression) 
and red (increased) in HLCs day 20 (HLCd20), day 24 (HLCd24) and hepatocytes 





5.5.4. Short reads snoRNA analysis 
 
During standard miRNA sequencing, a fraction of snoRNAs sequenced can be small and 
limited to short length reads of snoRNAs with adapters as a result of fractioning done before 
sequencing. The obtained dataset was created from the fraction of longer ncRNA and could be 
divided into short reads with adapters and full length reads. The short snoRNA reads cover 
15% of all mapped snoRNAs. In order to investigate whether the analysis of short (~20nt) 
reads alone give reasonable results for the snoRNA analysis, differential expression analysis 
on only the short snoRNA reads was performed and compared with results from all snoRNA 
reads analysis. An identified differentially expressed snoRNA with an FDR of 0.001 from 
short reads were in 85% to 90% also differentially expressed in the full data set. Of these, still 
significantly different reads, only a maximum of 1% showed a different direction in 
expression change. This result shows that datasets generated for the miRNA analysis can also 
be used to reliably investigate the snoRNome. To visualise a clear correlation between the 
analysed short reads and all dataset snoRNAs, a dot plot was prepared (Fig. 43). The figure 




Figure 43 Correlation of fold changes between short reads and all reads mapping 
snoRNA genes.  
Analysis of snoRNA genes with FDR below 0.001; y-axis – logarithmic transformation of 
fold change of short reads only analysis, x-axis –  logarithmic transformation of fold change 
when considering all reads. Comparison of results from differentially gene expression 
analysis of HLCd20 and hepatocytes- in black, HLCd24 and hepatocytes – in red and in blue 
HLCd20 and HLCd24 (Skrzypczyk et al., 2017, manuscript in preparation). 
 
5.5.5. New gene candidates 
 
In the expressed loci that do not overlap gene or repeats annotations, it was possible to 
identify novel ncRNAs. These include 9 novel box C/D snoRNAs, 10 box H/ACA snoRNAs 
and 4 detected with structurally conserved regions (detected by RNAz software based on 
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support vector machines). Most of the new RNA sequences were conserved during evolution 
(Table 5). One box C/D snoRNA could only be identified in humans and three snoRNA 
families of each type are identified as primate-specific. Another seven families are also 
conserved in other eutherian species. A list of all annotated novel genes is provided in Table 
6. 
 
Table 5 Conservation of novel RNA candidates 
Method  Type  Count  Conservation  
snoReport CD 3 Boreoeutheria 

























Table 6 List of novel ncRNAs 
Position  Type Host gene  
chr1:113824553-113824673 HACA-snoRNA PTPN22 
chr1:181362152-181362263 HACA-snoRNA - 
chr1:40773163-40773278 HACA-snoRNA - 
chr1:153969534-153969592 CD-snoRNA CREB3L4 
chr3:168093129-168093244 HACA-snoRNA GOLIM4 
chr3:79560919-79561042 HACA-snoRNA ROBO1 
chr5:163294865-163294994 HACA-snoRNA RP11-541P9.3 
chr5:6757562-6757670 HACA-snoRNA - 
chr7:33591095-33591209 HACA-snoRNA BBS9 
chr9:122744852-122744927 CD-snoRNA - 
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chr11:71300629-71300727 CD-snoRNA - 
chr11:98956624-98956737 CD-snoRNA - 
chr13:59018873-59018998 HACA-snoRNA - 
chr17:39725613-39725692 CD-snoRNA ERBB2 
chr21:39475295-39475353 CD-snoRNA SH3BGR 
chrY:6441667-6441790 HACA-snoRNA - 
chr5:116653307-116653431 CD-snoRNA - 
chr9:79487404-79487526 CD-snoRNA - 
chr10:30457496-30457617 CD-snoRNA MAP3K8 
chr11:2224892-2225019 RNAz - 
chr16:636684-636856 RNAz MCRIP2 
chr5:97539290-97539410 RNAz LINC01340 


















6. Discussion  
6.1. Methodical strategy 
 
The iPSCs were discovered 10 years ago, and during this time cell reprogramming techniques 
changed. Currently, episomal vectors are the most popular tool to obtain a temporary 
overexpression of reprogramming factors. Traditionally, the electroporation method was 
performed to deliver those vectors to reprogramming cells. In the current study, episomal 
vectors were delivered to the reprogrammed cells using Lipofectamine 3000. A combination 
of repeated lipotransfection and the highly efficient reprogramming factors makes the 
generation of iPSCs effective and safe. The transfection method used here can be successfully 
reproduced by other laboratories worldwide, without using expensive machines for 
electroporation. Additionally, there was no symptom of cytotoxicity during reprogramming 
which makes this method stable and predictive.  
A cell’s gene expression changes in time and condition-specific situations. It is an important 
issue to completely understand the regulatory mechanisms of gene expression during human 
development. This study can have a potential implication in clinical medicine. During recent 
years, miRNAs profiles were discovered in many cell types. Several researchers identified 
that miRNAs are involved in differentiation and cancerogenesis. However, the mechanism of 
miRNA orchestrating the hepatic differentiation of stem cells is still poorly understood. 
Therefore, identification of such miRNAs may be used to improve the generation of stem cell-
derived hepatocytes for cell replacement therapies. In the current study, a new line of iPSCs 
was differentiated into hepatocytes and ncRNA profiling was performed. Several methods 
were developed for miRNAs quantification. NcRNA sequencing using the Illumina platform 
was the chosen strategy here. This approach is a reliable procedure in order to identify 
miRNAs that are differentially expressed between the cell types. However, this method 
cannot predict the functional relevance of the discovered differentially expressed miRNAs. 
Hence, functional studies and target validation have to be performed in order to assert how 
miRNA contributes to cell condition. Nevertheless, ncRNA sequencing also allows the 
detection of novel genes. To filter new ncRNA candidates, the bioinformatic approach was 




6.2. Characterisation of generated iPSCs 
 
After the generation of new iPSCs, it was necessary to validate their pluripotent character 
with the standard pluripotency tests. For this purpose, the colonies were assessed for 
expression of pluripotency markers, the ability for differentiation into three germ layers, and 
genetic stability following reprogramming. 
The iPSCs showed ESCs-typical morphology, expression of pluripotency markers, and the 
ability to differentiate into all three germ layers. Karyotyping reveals that these iPSCs have no 
chromosomal aberrations. The reprogramming process did not cause the incorporation of 
vector caring genes. The obtained new cell line had a stabile karyotype during the long-term 
culture. To our knowledge, this is the first report of the generation of iPSCs using 
oriP/EBNA1 (Epstein–Barr nuclear antigen-1)-based episomal vectors combined with 
repeated lipotransfection. This method is a combination of many pluripotency inducers and 
gentle transfection using liposomes. The episomal vectors were delivered twice in order to 
increase the reprogramming efficiency. This method can be successfully applied in many 
laboratories without the necessity of using an electroporator. An evaluation of generated cells 
was done by a comparison with commercial iPSCs (Life Technologies). The newly derived 
iPSCs were exhibit morphology, proliferation, pluripotency markers, and differentiation 
potential comparable to the commercial iPSCs line. Comparison with the ESCs would be 
interesting as well, however, the University of Leipzig has no license for the cultivation of 
ESCs.  
 
6.3. Hepatic differentiation of iPSCs 
 
6.3.1. Characterisation of HLCs 
 
To determine the hepatic characteristic of the cells after differentiation, hepatic markers and 
genes were examined, as well as hepatic functions. The obtained HLCs expressed mature 
hepatic markers: HNF4a, ALB, CK18 and MRP2, but also the fetal marker AFP. A gene 
expression analysis showed that expression of AFP was the highest in the HLCs when 
compared to the HepG2. There was no expression of AFP in the hepatocytes, while all mature 
hepatic genes – A1AT, HNF4a and Albumin were highly expressed. In the HLCs, expression 
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of HNF4a was lower than HepG2. However, A1AT and Albumin expression were 
approximately the same as in HepG2. The HLCs could store glycogen as shown by PAS 
staining and metabolise ICG. These functional tests revealed a hepatic characteristic of 
obtained cells. On the other hand, expression of the fetal liver marker AFP, indicated 
inhibition of hepatic maturation. Amount of characterisation tests was reduced due to limited 
funds. However, these results are consistent with the previous description of HLCs obtained 
with this differentiation protocol (Baxter et al., 2015; Yu et al., 2012). 
 
6.3.2. Protocol with HNF4a overexpression 
 
Hepatic differentiation protocol of iPSCs was changed by adding HNF4a overexpression as 
an attempt to improve the process since HNF4a is a master transcriptional factor regulating 
hepatic differentiation. The results showed that HNF4a overexpression caused local storage of 
the transcription factor in the cells cytosol, however, it was limited to a few spots in the 
culture vessels of the cells. The episomal vectors are normally lost during cell division, but 
during differentiation cells stop their proliferation. The observed overexpression could be a 
result of vector storage during differentiation. The obtained HLCs expressed hepatic markers: 
Albumin, HNF4a, CK18, AFP and could store glycogen and metabolise ICG, which shows 
hepatic cell commitment. Comparison of the hepatic gene expression indicates that HLCs 
from the modified protocol were expressing: A1AT, HNF4a, Albumin and AFP on the lower 
level. The evaluation of hepatic differentiation efficiency by image analysis of double positive 
cells for HNF4a and ALB markers on the slides demonstrates that there is no difference 
between the two protocols. The area covered by “mature” HLC was around 30 % of the slide. 
It was shown that hepatic differentiation efficiency varies between protocols and the iPSCs 
lines used for the study (Kajiwara et al., 2012). Nevertheless, modification of protocol by 
HNF4a overexpression was not enough to improve hepatic differentiation and maturation.  
 
6.3.3. Differentially expressed miRNA 
 
In this study, the miRNA profiles of iPSCs-derived HLCs were investigated. To detect 
potential inhibitors of hepatic maturation, obtained miRNAs profiles were compared. 
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Previously, some attempts to explore miRNA profiles during hepatic differentiation of ESCs 
were made (Kim et al., 2011; Raut & Khanna, 2016). However, analysis of ncRNA 
sequencing from iPSCs derived HLCs were not investigated before. The comparison of the 
miRNA profiles reveals that hepatic specific miRNAs (miR-122-5p, miR-27b-3p, miR-23b-
3p, miR-148-3p, miR-146b-5p and miR-194-5b among others) are expressed at the lower 
level in the HLCs compared to hepatocytes. However, expression of those hepatic specific 
miRNAs rose during the differentiation process in the HLCs when day 20 and day 24 were 
compared. Additionally, fetal hepatic miRNAs (miR-23a-3p, miR-30a-5p, miR483-3p, miR-
92b-3p among others) are expressed in the HLCs especially on day 24 of differentiation, 
indicating that HLCs undergo hepatic differentiation into immature hepatocytes. Analysis of 
differentially expressed miRNAs implicates that upregulated miRNAs in the HLCs when 
compared to hepatocytes are involved in differentiation, inhibition of proliferation, and 
maintaining epithelial phenotype. Remarkably, analysis of differentially expressed miRNAs 
between HLCs day 20 and day 24 shows that in HLCs day 24, miR-199 is strongly 
upregulated along with miR-214. These miRNAs are regulators of skeleton formation, 
cardiogenesis, and cancer (Gu & Chan, 2012). An inhibition of miR-199a-5p expression, 
improved the hanging drop hepatic differentiation of ESC and liver repopulation ability of 
obtained HLC (Möbus et al., 2015). Authors of this research also identified new targets of 
miR-199a-5p which directly regulate hepatocyte development. This finding might have 
implications that improve hepatic maturation in the future. MiR-199a was also identified as 
being involved in liver fibrosis through deposition of an extracellular matrix and a pro-fibrotic 
cytokines release, together with the miR-200 family (Murakami et al., 2011; Jiang, Ai, Wan, 
Zhang, & Wu, 2017). The miR-200 family (miR-200a, miR-200b, miR200c, miR-141, miR-
429) is known epithelial marker which was recently linked to the inhibition of EMT by 
repressing ZEB1, ZEB2 and Snail (Gregory et al., 2008). Expression of those miRNAs is 
visible in HLCs and could inhibit EMT during maturation. It has been previously reported in 
the study of MSC-derived HLCs by Raut et al. (human umbilical cord Wharton’s jelly- 
derived MSCs) that EMT related miRNAs had elevated expression in the last days of hepatic 
differentiation (Raut & Khanna, 2016). During the embryo development, both EMT and 
Mesenchymal to Epithelial Transition (MET) are essential processes. EMT can be 
characterised by the repression of the E-cadherin expression, change in morphology and loss 
of cell adhesion. At the same time, cells increase migration and expression of mesenchymal 
markers like N-cadherin, Vimentin and Fibronectin (Lamouille, Subramanyam, Blelloch, & 
Derynck, 2013). During liver development, the EMT event is visible in stroma cells when the 
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liver supports haematopoiesis (Chagraoui, Lepage-Noll, Anjo, Uzan, & Charbord, 2003; 
Sicklick et al., 2006; Li, Zheng, Sano, & Taniguchi, 2011). Inhibition of EMT can potentially 
block hepatic differentiation. However, this hypothesis must be interpreted with caution. 
During liver development, EMT is a natural process of hepatic differentiation, but it is also 
involved in cancerogenesis (Yoshida, 2016; Du et al., 2014). There are several possible 
explanations for this result. For example, low differentiation efficiency leads to a 
heterogeneous population after differentiation, including other kinds of endodermal cells, as 
speculated before (Godoy et al., 2015). Nevertheless, evidence of EMT inhibition was 
previously reported and should be resolved by additional studies. Some attempts have already 
been made. The SNAI-1 mesenchymal transcription factor (Snail, inducer of EMT) proved to 
be important for hepatic cell maturation (Goldman, Valdes, Ezhkova, & Gouon-Evans, 2016). 
E-cadherin (epithelial cadherin) overexpression during hepatic differentiation of mice ESCs 
influences vascular network structures by accelerating angiogenesis (Hu et al., 2013).  
In the present study, elevated expressed miRNAs have been similar to those described during 
ESCs hepatic differentiation by Kim et al. (Kim et al., 2011). The obtained HLCs had a high 
expression of miRNAs (miR-21, miR-214, miR-216a) involved in phosphatidylinositol-3-
kinases (PI3K) pathway. However, results of this experiment show no evidence of 
upregulation of those miRNAs in the adult hepatocytes. At the same time, analysis of the 
differentially expressed miRNAs from hepatocytes by DIANA miRpath shows that they 
control the PI3K pathway. This indicates that the PI3K signaling pathway might be 
maintained in the hepatocytes by different miRNAs during differentiation and in the mature 
state. Another highly upregulated miRNA in HLCs- miR-181, which is also abundant in the 
fetal liver, was linked to hepatocarcinoma (Ji et al., 2009). In cancer cells, the expression of 
an epithelial cell adhesion molecule (EpCAM) was related to high level of miR-181. This 
miRNA, however, targets the epithelial gene caudal type homeobox transcription factor 2 
(CDX2), which promotes EMT. It suggests that the expression of miR-181 might be essential 
for the balance between the epithelial and mesenchymal phenotype in hepatocytes.  
A crosslink between miRNA profiles and pathways related to differences in cells is difficult 
to assess. Many of those miRNAs still do not have validated targets. An analysis of a large 
number of genes can lead to a statistical bias. Nevertheless, KEGG pathways related to 
differentially expressed miRNAs were identified by using the DIANA-miRPath v3.0 online 
tool (Vlachos et al., 2015). The analysis of KEGG pathways related to differentially expressed 
miRNAs in hepatocytes shows that they control pathways, as mentioned before in regards not 
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only to PI3K-Akt signaling but also with focal adhesion, TGF-beta signaling pathway and the 
Thyroid hormone signaling pathway. It was shown that transient hypothyroidism increased 
expression of miRs-1, 206, 133a and 133b in liver cells (Dong et al., 2010). Interestingly, 
miR-1-3p and miR-133a are in the group of differentially expressed miRNAs from the HLCs. 
An appropriate thyroid hormone level is critically important for development and 
differentiation. It is also well known that the liver regulates the hormone level by secreting 
carrier proteins (Malik & Hodgson, 2002). The potential influence of the thyroid hormone on 
hepatic differentiation should be resolved in future research. The differentially expressed and 
enriched miRNAs from the HLCs compared to the hepatocytes, control the following: fatty 
acid biosynthesis and metabolism, ECM-receptor interaction, proteoglycans in cancer, the 
Hippo signalling pathway, the adherens junction, lysine degradation, prion diseases, viral 
carcinogenesis, pathways in cancer, the p53 signaling pathway, and the cell cycle. Fatty acid 
biosynthesis and metabolism is a typical liver function, which can be accelerated by insulin 
added to the medium. The hippo signaling pathway is a central mechanism that regulates 
organ size by control of cell proliferation and apoptosis (Pan, 2010). The HLCs miRNAs 
control those pathways as a result of the differentiation process. Furthermore, HLCs have fetal 
character and tissue remodelling processes take place. Pathways listed here could be involved 
in any differentiation process, however this result shows again that the obtained HLCs are 
immature and undergo many metabolic changes. Some differentially expressed miRNAs in 
HLCs are involved in cancer. Additional research must be done to clarify miRNAs interplay 
between genes and chemical molecules used in differentiation. The hepatic differentiation 
process is still limited; however, the ncRNA expression profiles obtained in this study will be 
helpful in understanding the mechanism of differentiation and thus indicate the way of future 
research.  
 
6.3.4. Differentially expressed snoRNA 
 
Strong evidence of differentially expressed snoRNAs was found in the dataset. Most of those 
snoRNAs belong to the box C/D class. There is evidence that small fragments derived from 
the box C/D snoRNAs accumulate in cells having conserved patterns. This sdRNA have been 
shown to influence splicing or translation (Scott et al., 2012; Falaleeva & Stamm, 2013b). 
Additionally, it has been shown that patients with metastatic prostate cancer have a higher 
expression of SNORD78 and its derived small fragments (Martens-Uzunova et al., 2015). 
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This demonstrates that the differentially expressed snoRNAs can be useful diagnostic 
biomarkers for many conditions. In this study, differences in expression of many snoRNAs 
that potentially can be differentiation markers were reported, nevertheless, future 
investigation is needed. Many of the differentially expressed snoRNAs belong to an imprinted 
locus (24 copies of SNORD115, 7 copies of SNORD113, 18 copies of SNORD114 and 20 
copies of SNORD116). Previously, hepatic snoRNAs from imprinted regions were compared 
with 10 other human tissues by Castle et al. (Castle et al., 2010). Expression of imprinted 
snoRNA genes was low in the liver. However, in this study, copies of SNORD113, 
SNORD114 and SNORD116 were downregulated in the liver compared to HLCs, while all 
copies of SNORD115 were upregulated. This is in line with later reported analysis of the 
Prader-Willi Syndrome locus by Galiveti et al., where SNORD115 had higher expression than 
SNORD116 in the liver (Galiveti, Raabe, Konthur, & Rozhdestvensky, 2014). What is 
interesting in other endodermal tissues (small intestine, colon, spleen, lungs and trachea) is 
that expression of SNORD115 is lower and SNORD116 higher. Moreover, it was shown that 
SNORD115 can regulate SNORD116 expression and activity (Falaleeva, Surface, Shen, La 
Grange, & Stamm, 2015). Intriguing correlation between our data and previous research can 
be noticed. These findings, while preliminary, suggest that there are metabolic changes in 
mature hepatocytes, which can potentially lead to a characteristic snoRNA expression pattern. 
Another aspect of a differential snoRNA expression is that it can lead to specialised 
ribosomes in the hepatocytes. The liver is an essential organ that has multiple functions. 
Highly active metabolic ribosomes of hepatocytes might require special rRNA modifications. 
A recent investigation of sequencing data generated across the circadian cycle in the mouse 
liver indicates cyclical variations of snoRNAs (Aitken & Semple, 2017). Furthermore, those 
variations were independent of the host gene expression and identified SNORD115 as a 
cyclical snoRNA.  
Additionally, shown here analysis of short snoRNA reads (with adapters) and a comparison to 
the whole snoRNAsome is a very useful methodological result. Results show that the 
presence of snoRNAs during standard miRNA sequencing can be analysed with 
approximately 85% accuracy. Differential expression of snoRNAs can be detected and 
quantified reliably from standard short ncRNA sequencing data and does not require 






6.4. Novel snoRNA genes 
 
From obtained sequencing data, 19 candidate snoRNA genes and four unclassified ncRNAs 
were identified. Conservation analysis shows that most novel genes are evolutionarily young, 
suggesting that the repertoire of small structured RNAs is subject to rapid expansions. 
Potentially these newly identified snoRNAs are exclusively expressed in endodermal linage 
and therefore have not been detected before. The novel snoRNAs require further investigation 
for their functions in hepatocytes. Recent research on snoRNAs revealed that functions of 
snoRNAs go beyond guidance of chemical modification of ribosomal and snRNAs. 
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The liver is a crucial human organ with a complex architecture. Although the liver has great 
regeneration potential, deadly liver diseases are associated with irreversible hepatocytes 
damage. Currently, a liver transplant is the only treatment for liver failure. A shortage of 
donors forced extensive research for alternative treatments. The most promising hepatocyte 
source could be obtained from the differentiation of induced pluripotent stem cells (iPSCs). 
This technology can give us great amounts of pluripotent cells, without ethical restrictions, 
which could be available in a variety of haplotypes to minimize the possibility of rejection. 
There are many reprogramming protocols available. However, there is still no standardised 
method to obtain clinical grade iPSCs. From those stem cells, it is possible to obtain hepatic-
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like cells (HLCs) by direct differentiation in vitro. HLCs express multiple hepatocyte-specific 
features, but their names signal that they still show fetal liver identity. A variety of hepatic 
differentiation protocols were described, although the process of hepatic differentiation must 
be improved in order to be translated into the clinic. Along with genes, microRNA (miRNA) 
is the well-known controller of cell fate. MiRNA is a type of non-coding RNA (ncRNA) 
which can influence gene transcription by inhibiting gene expression. In contrast to genes, 
many of the miRNAs can affect up to thousands of genes simultaneously. Another group of 
ncRNA, which is a subject of potential differences are small nucleolar RNA (snoRNA). 
SnoRNA are involved in RNA chemical modifications by acting as a guide, mostly for 
ribosomal RNA (rRNA), but some of them have additional functions.  
In this study, a new iPSCs line was generated from skin fibroblasts using lipotransfection of 
episomal vectors. This method is free from exogene integration and shows low cytotoxicity. A 
pluripotency of generated cells was confirmed by morphological assessment, 
immunocytochemical staining, and spontaneous differentiation assay. To be sure that the 
chromosomes of the cells were not changed, karyotype analysis was performed. Next, HLCs 
were derived from those iPSCs using a four-stage hepatic differentiation protocol. The 
obtained HLCs were then characterised using a hepatic gene expression analysis, among 
others. Cells after differentiation express mature and fetal hepatic markers, which is consistent 
with previous results. The attempt to improve differentiation using transient overexpression of 
master hepatic transcription factor – HNF4α, was not sufficient, as shown by gene expression 
analysis and whole slide scanning.  
Previous studies failed to point out the genetic inhibitors of hepatic maturation and non-
coding RNA (ncRNA) profiles of iPSCs – derived HLCs were not investigated. In this study, 
the sequencing of ncRNA was performed in order to compare the expression profiles of HLCs 
on two stages of differentiation (Day 20 and 24) with mature hepatocytes. The obtained 
results indicate that HLCs express miRNA, which control hepatic differentiation and maintain 
their fetal liver character. In comparison to mature hepatocytes, differentially expressed 
miRNAs in HLCs control the pathways of fatty acid metabolism and synthesis, proteoglycan 
in cancer, the Hippo signaling pathway, ECM-receptor interaction and adherens junction. 
Some of those highly expressed miRNAs can potentially block maturation by inhibiting 
epithelial-mesenchymal transition (EMT) which has a huge impact during hepatic 
differentiation. However, this should be resolved in future research. In this work, 
differentially expressed snoRNA were also identified. A total of 68% of differentially 
98 
 
expressed snoRNAs was box C/D class. This is interesting because this snoRNA class was 
previously indicated as capable to be processed by a miRNA processing pathway. Many of 
the differentially expressed snoRNAs belong to the imprinted loci, in which a different 
expression in a human was analysed before. In obtained dataset, copies of SNORD115 were 
upregulated in a liver, but not in HLCs, which is consistent with an earlier comparison of a 
liver and other endoderm organs. Additionally, an analysis of obtained sequencing data 
allowed for a discovery of 19 novel snoRNA genes. 
In summary, this work shows a new approach to the reprogramming of a fibroblast and 
investigates the involvement of miRNAs and snoRNAs in the dynamics of hepatic 
differentiation. Novel snoRNA genes were annotated which enriches the pool of known 
snoRNA. A dataset generated here could also be the foundation for a hepatic-specialised 
ribosomes theory. This study has shed a light on the molecular and regulatory mechanisms 
that underlie the complex process of liver differentiation. The results obtained here will 
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Table 7 List of differentially expressed miRNA 
Differentially expressed miRNAs (top 100): marked in bold are characteristic for one type of 
comparison, in colour miRNAs specific for: mature liver, fetal liver, EMT inhibition, Pi3K signalling 

















































































































































































































































































































































































































































































































































































Table 8 List of differentially expressed snoRNA 
HLCs day 20 vs. Hepatocytes and HLCs day 24 vs. Hepatocytes 
snoID 0310  
snoID 0319  
snoID 0324  
snoID 0350  
snoID 0369  
snoID 0370 
snoID 0372 
 snoID 0375  
snoID 0378  
snoID 0381  
snoID 0388  
snoID 0400 
snoID 0435  
snoID 0662  
snoID 0668  
snoID 0681  
snoID 0684  
snoID 0688 
snoID 0720  
snoID 0723  
snoID 0730  
snoID 0731  
snoID 0749  
snoID 0757 
snoID 0760  
snoID 0766  
snoID 0792  
snoID 0796  
snoID 0826  
snoID 1103 
snoID 1104  
snoID 1105 
snoID 1106 



















































































































































































































































HLCs day 20 vs. Hepatocytes only 
snoID 0318  
snoID 0371  
snoID 0379  
snoID 0386  
snoID 0392  
snoID 0409 
snoID 0709 
snoID 0714  





























































Erklärung über die eigenständige Abfassung der Arbeit 
 
 
Hiermit erkläre ich, dass ich die vorliegende Arbeit selbstständig und ohne unzulässige Hilfe 
oder Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. Ich versichere, dass 
Dritte von mir weder unmittelbar noch mittelbar eine Vergütung oder geldwerte Leistungen 
für Arbeiten erhalten haben, die im Zusammenhang mit dem Inhalt der vorgelegten 
Dissertation stehen, und dass die vorgelegte Arbeit weder im Inland noch im Ausland in 
gleicher oder ähnlicher Form einer anderen Prüfungsbehörde zum Zweck einer Promotion 
oder eines anderen Prüfungsverfahrens vorgelegt wurde. Alles aus anderen Quellen und von 
anderen Personen übernommene Material, das in der Arbeit verwendet wurde oder auf das 
direkt Bezug genommen wird, wurde als solches kenntlich gemacht. Insbesondere wurden alle 
Personen genannt die direkt an der Entstehung der vorliegenden Arbeit beteiligt waren. Die 
aktuellen gesetzlichen Vorgaben in Bezug auf die Zulassung der klinischen Studien, die 
Bestimmungen des Tierschutzgesetzes, die Bestimmungen des Gentechnikgesetzes und die 
allgemeinen Datenschutzbestimmungen wurden eingehalten. Ich versichere, dass ich die 
Regelungen der Satzung der Universität Leipzig zur Sicherung guter wissenschaftlicher 





.................................                                                                        .................................... 









This thesis was performed in the Cell Techniques and Applied Stem Cell Biology Department 
of Leipzig University, Germany during the years 2014-2017. This project was founded by the 
EU Marie Sklodowska-Curie Actions BIOART Project grant no.316690, EU-FP7-PEOPLE-
ITN-2012 
 
First of all, I would like to thank Professor Augustinus Bader for giving me the opportunity to 
do my PhD in his laboratory and for employment in the Bioart Project. His guidance and 
support during the past years have been invaluable for which I am especially grateful. 
I am also sincerely thankful to my second supervisor Professor Peter Stadler who gave me the 
opportunity to explore bioinformatic during my PhD studies. He was giving me enormous 
patience, guidance and warm encouragement.  
I am grateful to Dr. Shibashish Giri for his support. Without his help, it would not have been 
possible to be part of Bioart project without him. 
I would like to acknowledge Ilona Krystel for being there for me through the whole time and 
for the helps she provided during these past years in the lab. Her good advice has always been 
helpful for the progress of this study. 
This thesis would not have been possible without all my collaborators Dr. Stephanie Kehr and 
Dr. Stephan Bernhart which are thanked for their encouragement and guidance in 
bioinformatics. Other special thanks to Dr. Nico Scherf for his help with the image analyses. I 
would like to extend special thanks to Dr. Heidrun Holland for her kindness and help with 
karyotyping and scientific discussions. 
Last, but by no means least, I want to profoundly thank my family and friends for their 
continuous support, love, and belief in me.  
 
